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ABSTRACT

Holloway, Laurin Nicole. M.S., Department of Biological Sciences, Microbiology and
Immunology Program, Wright State University, 2009. Host Defense Mechanisms
Against Mycobacterium tuberculosis.

Mycobacterium tuberculosis is one of the world’s most infectious diseases.
Approximately 2 million people die each year from Mycobacterium tuberculosis
infection and one-third of the world’s population remains infected. For decades research
has focused on uncovering the tactics used by Mycobacterium tuberculosis to evade host
immune responses and defense mechanisms used to fight tuberculosis infection. The
following review focuses on the host defense mechanisms used to combat
Mycobacterium tuberculosis with an emphasis placed on the roles that Toll-like receptors
(TLRs), T cells (γδ, CD4+, CD8+), and macrophages play in mounting the innate and
adaptive immune responses necessary to eradicate this disease. The challenges of
designing an effective vaccine to fight Mycobacterium tuberculosis infection and the two
first-line anti-tuberculosis inhalant drugs, Isoniazid (H) and Rifampicin (R) are also
discussed.
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SIGNIFICANCE
Mycobacterium tuberculosis is a devastating disease that affects a large portion of
the world’s population. The fight against Mycobacterium tuberculosis infection is
currently a battle that is lifelong given that at the moment there is no vaccine that is 100%
effective or a cure. The fact that latent Mycobacterium tuberculosis infection continues
to pose the threat of reactivation at any moment puts more individuals at risk of
contracting Mycobacterium tuberculosis infection. With the increasing number of
immigrants entering into the United States from countries where adequate healthcare is
minimal to nonexistent, it is vital that all of the necessary precautions are taken to prevent
the incidence of Mycobacterium tuberculosis infection.
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INTRODUCTION
The likelihood of becoming infected with Mycobacterium tuberculosis is
multifactoral (Raja, 2004). Mycobacterium tuberculosis is the second leading cause of
death among all infectious diseases worldwide. Approximately 2 million people die each
year from Mycobacterium tuberculosis (Davis et al., 2007) and one-third of the world’s
population remains infected with latent disease (van Crevel et al., 2002).
Naturally there are individuals who are more susceptible to mycobacterial
infections than others. Individuals reported as having an increased risk of contracting
mycobacterial infections include individuals that have suffered chronic renal failure,
individuals with insulin-dependent diabetes, individuals undergoing immunosuppressive
therapy, residents of prisons and homeless shelters, intravenous-drug users, and
individuals infected with HIV (Horsburgh, 2004). These specific individuals’ increased
susceptibility to Mycobacterium tuberculosis may stem from a decrease in their immune
system’s ability to prevent infection, progression to primary infection, and infection
reactivation (Horsburgh, 2004).
The objective of the following review is to examine the host defense mechanisms
used to combat Mycobacterium tuberculosis with an emphasis placed on the roles that
Toll-like receptors (TLRs), T cells (γδ, CD4+, CD8+), and macrophages play in mounting
the innate and adaptive immune responses necessary to eradicate this disease.
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INITIAL MYCOBACTERIUM TUBERCULOSIS INFECTION
Mycobacterium tuberculosis can cause infection anywhere within the body,
although it mainly takes hold and resides within the lungs of infected individuals (van
Crevel et al., 2002). Consequently, the route of infection plays an important role in
determining how signal transduction, immune activation, and the intracellular survival of
Mycobacterium tuberculosis occur (van Crevel et al., 2002). Mycobacterium tuberculosis
is the most virulent of mycobacteria (Pieters et al., 2002). Mycobacteria are slow
growing organisms that limit themselves to mainly infecting macrophages of the host
(Pieters et al., 2002), specifically macrophages of the lung (alveolar macrophages) (van
Crevel et al., 2002). Mycobacteria reside in structures known as phagosomes. Normally
bacteria ingested by alveolar macrophages are destroyed within lysosomes that fuse with
phagosomes. In contrast, Mycobacterium tuberculosis prevents lysosomal fusion with
phagosomes. The failed fusion of these two structures prevents the formation of a third
structure known as the phagolysosome, consequently leading to the mycobacteria’s
avoidance of degradation and destruction within the macrophage, contributing to the
survival of Mycobacterium tuberculosis infection (Pieters et al., 2002). This ability to
evade destruction by the alveolar macrophage limits the immune response of the host to
containing the infection, not eliminating it (Flynn et al., 2001).
Initiation of Mycobacterium tuberculosis infection begins with the inhalation of
tubercle bacilli. Following inhalation, the tubercle bacilli are ingested by alveolar
macrophages, resulting in either their destruction or persistence. The tubercle bacilli that
3

are capable of escaping destruction then multiply and disrupt the function of the alveolar
macrophage. When the actions of the alveolar macrophage become disrupted, other
inflammatory cells programmed to prevent the spread of infection are then recruited to
the site of infection within the lungs. Following inhalation of the tubercle bacilli, the
mycobacteria are either destroyed, in which case no infection occurs, or the mycobacteria
remain viable. In the event that the mycobacteria are not destroyed, a primary complex
forms. The primary complex consists of Mycobacterium tuberculosis infiltrate and a
draining lymph node. The primary complex gives rise to the positive skin test that marks
the Mycobacterium tuberculosis-specific T cell response, uncovering the existence of
infection. Once Mycobacterium tuberculosis infection has been established, the infection
is usually stabilized and goes into latency. In some cases however, the infection is not
stabilized and active disease develops (primary tuberculosis infection). Active
tuberculosis infection in turn uses one of two methods to remain active within the host.
Active tuberculosis disease either remains localized, keeping infection limited to the
lungs, or it disseminates and travels to other areas of the body. In the event of
Mycobacterium tuberculosis dissemination, infection stabilization and latency are still
possible however, large amounts of mycobacteria traveling throughout the body (miliary
tuberculosis) and meningitis remain risks. Although establishing a state of latency in a
Mycobacterium tuberculosis-infected individual is one means of controlling tuberculosis
infection, there always remains the risk of latent infection becoming reactivated in the
event of immune surveillance failure, thereby establishing post-primary Mycobacterium
tuberculosis infection (Fig. 1) (van Crevel et al., 2002).
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FIG. 1 Chronological events after inhalation of Mycobacterium tuberculosis. Adapted from van Crevel
et al., 2002
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CONTROLLING DISSEMINATION WITHIN THE INFECTED HOST
Granuloma Formation
Within 2 to 6 weeks following Mycobacterium tuberculosis infection, cellmediated immunity leads to granuloma formation (Raja, 2004; van Crevel et al., 2002).
Granulomas consist of lymphocytes and macrophages and are protective structures that
prevent the spread of infection to other parts of the body by localizing the inflammation
and damage. Granulomas surround the bacteria-infected cells and starve them from
nutrients that are essential for their survival. In the case of Mycobacterium tuberculosis
infection, granulomas function to keep the infection localized within the lungs (Salgame,
2005). Tuberculous granulomas consist of epitheliod macrophages, T cells (CD4+ and
CD8+), B cells, and fibroblasts (Fig. 2) (Co et al., 2004 as reviewed by Salgame, 2005).
Lymphocytes and multinucleated Langerhans giant cells may also be found in a central
location, surrounded by macrophages within the granuloma (Peters et al., 2003).
Formation of Three Granuloma Types
Three types of granulomas are capable of forming during a granulomatous
response to Mycobacterium tuberculosis: the noncaseating granuloma, the caseating
granuloma, and the reactivating granuloma (as reviewed by Salgame, 2005). Although
there is no direct evidence, the caseating and reactivating granulomas may arise from
noncaseating granulomas (Salgame, 2005). The noncaseating granuloma consists of
CD4+ and CD8+ T cells, B cells, and macrophages harboring few tubercle bacilli. This
specific granuloma is also surrounded by a layer of fibroblasts. Phagocytes carrying
6

tubercle bacilli from secondary infection sites migrate to these types of granulomas.
Caseating granulomas are the classic type of granulomas found within tuberculosis
patients. Caseating granulomas contain a central necrotic area that contains extracellular
bacteria surrounded by macrophages and phagocytes. This specific granuloma also
contains lymphoid follicle-like structures that are rich in T and B cells, and macrophages
that contain tubercle bacilli. A reactivating granuloma is a very disorganized granuloma
type that exhibits enhanced Mycobacterium tuberculosis replication. The reactivating
granuloma is the least effective in fighting against Mycobacterium tuberculosis infection
(Fig. 2) (Salgame, 2005).

FIG. 2 The three types of granulomas capable of forming during the granulomatous response to
Mycobacterium tuberculosis. Adapted from Salgame, 2005

Cytokines Involved in the Host Defense Response Against Mycobacterium tuberculosis
Interleukin 1 Beta (IL-1β)
IL-1β is a proinflammatory cytokine produced mainly by monocytes,
macrophages, and dendritic cells during an immune response to Mycobacterium
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tuberculosis (as reviewed by van Crevel et al., 2002). IL-1β is a key cytokine that plays
an important role in the acute phase response to mycobacterial infection by inducing
fever and cachexia (Raja, 2004). IL-1β is found in excess in tuberculosis patients (Schauf
et al., 1993 as reviewed by van Crevel et al., 2002). IL-1R type-1-deficient mice
displayed an increased susceptibility to mycobacterial outgrowth as well as defective
granuloma formation following infection with Mycobacterium tuberculosis (Juffermans
et al., 2000). This finding supports the importance of IL-1β in battling Mycobacterium
tuberculosis infection.
Interleukin 6 (IL-6)
IL-6 is a cytokine that possesses both pro- and anti-inflammatory properties
(VanHeyningen et al., 1997 as reviewed by van Crevel et al., 2002). IL-6 plays multiple
roles during an immune response, including inflammation, hematopoiesis, and
differentiation of T cells (Flynn et al., 2001). IL-6 is produced early in mycobacterial
infections but also has the potential to be harmful in these infections by inhibiting the
production of both TNF-α and IL-1β (Sallusto et al., 2000 as reviewed by van Crevel et
al., 2002). IL-6 knockout mice administered a low dose of aerosolized tubercle bacilli
maintained a higher bacterial load in the lungs and had decreased IFN-γ production
(Saunders et al., 2000). This decrease in IFN-γ production may contribute to the
increased susceptibility of IL-6-deficient mice to Mycobacterium tuberculosis infection.
Interleukin 12 (IL-12)
IL-12 is a very important cytokine with a key role in host defenses against
Mycobacterium tuberculosis. IL-12 is produced by activated macrophages following
phagocytosis of tubercle bacilli, triggering a T H 1 response and IFN-γ production. Mice
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deficient in the IL-12p40 gene were highly susceptible to intravenous infection with
Mycobacterium tuberculosis and were unable to control bacterial growth in the lung. The
mice also had a decreased survival time, reflecting the decrease in IFN-γ production
(Cooper et al., 1997). Humans with mutations in either the IL-12p40 gene or IL-12R
gene also showed a reduction in IFN-γ production, however, they were susceptible to
disseminated Bacillus Calmette-Guerin (BCG) and Mycobacterium avium infections, not
Mycobacterium tuberculosis (Ottenhoff et al., 1998). In a study with BABL/c mice, a
mouse strain highly susceptible to Mycobacterium tuberculosis infection, administration
of IL-12 early during infection significantly decreased the bacterial burden within their
lungs; however, the mice eventually succumbed to infection and died (Flynn et al., 1995).
In contrast, IL-12 had only marginal effects on the bacterial numbers in the lungs of
C57BL/6 mice (Cooper et al., 1995). The difference in the results presented by these two
sets of mice possibly result from the naturally resistant phenotype of the C57BL/6 mouse
to tubercle bacilli.
Interleukin 10 (IL-10)
IL-10 is an anti-inflammatory cytokine produced by macrophages and T cells
during Mycobacterium tuberculosis infection and antagonizes proinflammatory responses
by downregulating IFN-γ, TNF-α, and IL-12 production (Flynn et al., 2001).
Downregulation of proinflammatory cytokines by IL-10 inhibits CD4+ T cell responses
and the function of mycobacteria-infected antigen presenting cells (APCs) (Rojas et al.,
1999 as reviewed by Flynn et al., 2001). Intravenously BCG-infected IL-10 transgenic
mice developed a large bacterial burden in the spleen and liver (Murray et al., 1997),
contrasting from intravenously BCG-infected IL-10-deficient mice that displayed a
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bacterial burden comparable to the control (Murray et al., 1999). In human tuberculosis,
IL-10 production was shown to be higher in peripheral blood monocytes (PBMCs) of
anergic tuberculosis patients both before and following stimulation with purified protein
derivative (PPD). This finding suggests that Mycobacterium tuberculosis-induced IL-10
production is responsible for suppressing an effective immune response (Boussiotis et al.,
2000).
Transforming Growth Factor Beta (TGF-β)
TGF-β is an anti-inflammatory cytokine produced by monocytes following the
detection of mycobacterial products (Toossi et al., 1995). TGF-β is produced in excess
and is expressed at sites of active Mycobacterium tuberculosis infection (Toossi et al.,
1998). TGF-β acts by suppressing cell-mediated immunity. Deactivation of
macrophages by TGF-β downregulates IFN-γ and TNF-α production. The generation of
reactive oxygen intermediates (ROIs) and reactive nitrogen intermediates (RNIs) is also
inhibited by TGF-β (Toossi et al., 1998). TGF-β was present in the cellular infiltrate of
granulomas from patients with active Mycobacterium tuberculosis infection, suggesting
its involvement in the tissue damage and fibrosis that occurs in cases of tuberculosis
infection (Toossi et al., 1995).
Tumor Necrosis Factor Alpha (TNF-α)
TNF-α is an important mediator of inflammation during Mycobacterium
tuberculosis and is believed to play multiple roles in the immune and pathologic
responses to tubercle bacilli (Flynn et al., 2001). TNF-α is a proinflammatory cytokine
produced by macrophages, monocytes, and T cells upon stimulation with mycobacteria or
mycobacterial products (as reviewed by Flynn et al., 2001). TNF-α plays a key role in
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granuloma formation, macrophage activation, and possesses immunoregulatory
properties (as reviewed by van Crevel et al., 2002).
Influence of TNF-α on Granuloma Formation and Cytokine Production
Mice treated with a TNF-α-neutralizing antibody displayed an increase in IFN-γ
and IL-12 production and inducible nitric oxide synthase gene 2 (NOS2) expression
within lung granulomas (Chakravarty et al., 2008). The production of the proinflammatory cytokines IFN-γ and IL-12 increases inflammation within the granulomas,
defining a possible anti-inflammatory role for TNF-α. An increased production of the
anti-inflammatory cytokine IL-10 was also present within the granulomas. The presence
of IL-10 was hypothesized to decrease inflammation within the lungs of the TNF-αneutralized mice (Chakravarty et al., 2008).

To demonstrate the importance of TNF-α

in mounting a successful protective immune response against Mycobactrium tuberculosis
infection, BCG- immunized C57BL/6 mice were treated with TNF-α-neutralizing
hamster monoclonal antibody one week prior to intravenous infection with
Mycobacterium tuberculosis. Results from the experiment revealed that neutralization of
TNF-α impaired the ability of the mice to control the infection. Mice with a disruption in
the gene encoding for the 55kDa TNF receptor (TNFRp55-/-) were also unable to
control Mycobacterium tuberculosis infection (Flynn et al., 1995). Granulomas were
present in the lungs of both sets of mice; however they were necrotizing and contained an
overwhelming number of tubercle bacilli (Flynn et al., 1995). The findings from both
experiments define the importance of TNF-α in controlling Mycobacterium tuberculosis
infection.

11

TNF-α-Induced Production of Nitric Oxide (NO.)
It is hypothesized that TNF-α stimulates the production of nitric oxide (NO.) by
Mycobacterium tuberculosis-infected alveolar macrophages (Lyons, 1995 as reviewed by
Rich et al., 1997). To study the effect of TNF-α on Mycobacterium tuberculosis-infected
alveolar macrophages, human alveolar macrophages were infected with Mycobacterium
tuberculosis and incubated with TNF-α or pentoxifylline, a non-specific inhibitor of
TNF-α. The results showed that TNF-α alone increased Mycobacterium tuberculosisinduced NO. production by the alveolar macrophages. Pentoxifylline inhibited NO.
production by the alveolar macrophages as expected (Rich et al., 1997). The results from
this experiment show that TNF-α is required for NO. production by human alveolar
macrophages.
Role of TNF-α in Macrophage Apoptosis
TNF-α is hypothesized to contribute to the apoptosis of Mycobacterium
tuberculosis-infected macrophages. To investigate the role that TNF-α has in inducing
the apoptosis of Mycobacterium tuberculosis-infected macrophages, alveolar
macrophages obtained from bronchoalveolar lavage (BAL) of healthy subjects were
infected with either the attenuated (H37Ra) or virulent (H37Rv) Mycobacterium
tuberculosis strains. Following ELISA analysis of TNF-α levels, apoptosis of the
alveolar macrophages was measured using the TUNEL assay. Results from the
experiment showed significant TNF-α-induced apoptosis in both Mycobacterium
tuberculosis strains compared to the control. H37Ra however, displayed a higher level of
TNF-α-induced apoptosis than H37Rv (Balcewicz-Sablinska et al., 1998).
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Use of TNF-α Blockers
Systemic spillover of TNF-α can lead to unwanted inflammatory effects such as
fever, weight loss, tissue necrosis, and systemic shock (as reviewed by Bekker et al.,
1998). In tuberculosis patients receiving treatment, an increase of TNF-α was observed
in their plasma and it was accompanied by weight loss and clinical deterioration (Bekker
et al., 1998). In order to prevent or limit the deleterious effects of TNF-α, it is necessary
to downregulate systemic production of TNF-α and increase soluble TNF-α receptors
that block TNF-α activity (as reviewed by van Crevel et al., 2002).
To determine a cause for reduced apoptosis in H37Rv-infected alveolar
macrophages (Balcewicz-Sablinska et al., 1998), soluble tumor necrosis factor receptor
(sTNFR), a natural inhibitor of TNF-α, was analyzed for its release during
Mycobacterium tuberculosis infection. Results uncovered that there was a six-fold
increase in the amount of sTNFR present in the supernatant of H37Rv-infected alveolar
macrophages than the supernatant of H37Ra-infected alveolar macrophages (Fig. 3)
(Balcewicz-Sablinska et al., 1998).
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FIG. 3 Higher amount of sTNFR present in the supernatant of H37Rv-infected alveolar macrophages.
Adapted from Balcewicz-Sablinska et al., 1998

The presence of sTNFR in the supernatant of H37Rv-infected alveolar macrophages was
responsible for the decrease in TNF-α-induced apoptosis. Further anaylsis showed that
increased IL-10 production by the H37Rv-infected macrophages was responsible for the
accumulation of sTNFR in the supernatant. The increase in IL-10 inactivated TNF-α.
When anti-IL-10 antibody was added to the supernatant, sTNFR release was significantly
reduced and apoptosis was increased (Balcewicz-Sablinska et al., 1998). Taken together,
the findings from this experiment suggest a role for IL-10 in regulating the release of
sTNFR, ultimately controlling TNF-α-induced apoptosis of H37Rv-infected alveolar
macrophages.
Individuals treated with TNF-α blockers contract Mycobacterium tuberculosis
infection at an increased rate (Saliu et al., 2006). Three TNF-α-inhibiting drugs that are
currently being used for the treatment of autoimmune diseases such as rheumatoid
arthritis are being studied to determine their effect on the macrophage response to
14

mycobacterial infection (Harris et al., 2008). The three TNF-α-inhibiting drugs, also
known as TNF-α blockers, currently being used are adalimumab (Humira), infliximab
(Remicade), and etanercept (Enbrel). In whole blood samples stimulated with
Mycobacterium tuberculosis, Humira and Remicade inhibited T cell activation and IFN-γ
production whereas Enbrel did not (Table 1) (Saliu et al., 2006).

TABLE 1 Tumor-necrosis-factor blockade: effects on T cell activation (in terms of CD69 expression).
Adapted from Saliu et al., 2006

The difference in the effect that Enbrel has on T cell activation and IFN-γ production
suggest that it uses a different mechanism than the one used by Humira and Remicade,
possibly making it a better drug for the treatment of Mycobacterium tuberculosis
infection.
To determine the effect of Humira, Remicade, and Enbrel on phagosomelysosome fusion, human monocytes were infected GFP-BCG or PKH67 labeled H37Ra
and analyzed using confocal microscopy. In the absence of IFN-γ stimulation none of the
drugs had an effect on phagosome acidification in BCG-infected monocytes. However,
in H37Ra- and H37Rv-infected monocytes pretreated with IFN-γ, Humira, Remicade,
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and Enbrel all inhibited IFN-γ phagosome acidification (Harris et al., 2008). In
macrophages derived from PBMCs, Humira and Remicade inhibited phagosome
acidification in both untreated and IFN-γ-stimulated cells whereas Enbrel did not (Harris
et al., 2008). The difference in the macrophage types may have contributed to the
differences seen in the actions of the drugs.
Interferon Gamma (IFN-γ)
IFN-γ is a cytokine of great importance in controlling Mycobacterium
tuberculosis infection. IFN-γ is produced by T cells and NK cells and is required for the
protective response against Mycobacterium tuberculosis. The role of IFN-γ in opposing
survival of tubercle bacilli is to promote phagosome acidification and phagolysosome
fusion (as reviewed by Salgame, 2005).
Defective genes for IFN-γ in Mice and Humans
Humans defective in genes for IFN-γ or the IFN-γ receptor are highly susceptible
to mycobacterial infections, including Mycobacterium tuberculosis (Jouanguy et al., 1996
as reviewed by Raja, 2004). A lack of IFN-γ also poses a threat to the immune response
of mice. IFN-γ gene knockout mice infected with the virulent Mycobacterium
tuberculosis Erdman strain either intravenously or with aerosol were unable to control
infection, making them highly susceptible to Mycobacterium tuberculosis infection
(Cooper et al., 1993).
Implication of IFN-γ in NO. Production
IFN-γ is hypothesized to be involved in NO. production by activated monocytes.
In an experiment where Mycobacterium tuberculosis-infected PBMCs were stimulated
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with IFN-γ, NO. production was significantly increased (Sharma et al., 2004). The
finding from this experiment supports the hypothesis that IFN-γ induces NO. production.
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THE INNATE IMMUNE RESPONSE AGAINST MYCOBACTERIUM
TUBERCULOSIS
Apoptosis
Apoptosis, also referred to as programmed cell death, is a process that is
important to the development and maintenance of the immune system (Kelly et al., 2008).
In the host defense against Mycobacterium tuberculosis, apoptosis promotes microbicidal
activity in alveolar macrophages in an effort to remove the intracellular macrophage
niche (as reviewed by Gan et al., 2008). Macrophage apoptosis may contribute to the
innate immune system response against Mycobacterium tuberculosis by containing and
limiting the growth of tubercle bacilli (as reviewed by Kelly et al., 2008) by keeping the
membrane barrier intact (Gan et al., 2008). Macrophage necrosis, on the other hand,
releases viable tubercle bacilli from macrophages for the extracellular spread of infection
(as reviewed by Gan et al., 2008). Macrophage necrosis causes cell lysis and death,
leading to the inflammation that promotes tissue damage. The act of macrophage
necrosis is responsible for the recruitment of naïve macrophages that ultimately become
infected, thus prolonging Mycobacterium tuberculosis infection (Gan et al., 2008). The
attenuated H37Ra Mycobacterium tuberculosis strain induces macrophage apoptosis
while the virulent H37Rv Mycobacterium tuberculosis strain induces macrophage
necrosis (Fratazzi et al., 1997 as reviewed by Gan et al., 2008).
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Role of Bystander Apoptosis in Reducing the Spread of Mycobacterium tuberculosis
In an attempt to uncover how the process of apoptosis occurs in macrophages of
Mycobacterium tuberculosis-infected patients, Kelly et al. (2008) conducted a series of
three experiments. Based on findings from previous studies involving the attenuated
Mycobacterium tuberculosis strain H37Ra and human macrophage apoptosis, Kelly et al.
(2008) conducted an experiment that investigated if apoptosis also occurred in uninfected
bystander macrophages. Using the TUNEL staining technique, infected and uninfected
macrophages were co-cultured and observed for apoptosis for 24, 48, and 96h. Apoptosis
of infected macrophages was observed 24h postinfection with significant increases in
apoptosis seen at 48 and 96h postinfection. The results also showed bystander apoptosis
in the uninfected macrophages occurring at 48 and 96h postinfection (Fig. 4) (Kelly et al.,
2008).

FIG. 4 Mycobacterium tuberculosis strain H37Ra induces bystander apoptosis in uninfected human
macrophages. Adapted from Kelly et al., 2008

To determine if bystander apoptosis of the uninfected macrophages was due to the release
of soluble factors, supernatant from infected apoptotic macrophages was collected and
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filtered to remove any mycobacteria. The supernatant was then added to the uninfected
macrophages and the level of apoptosis was measured using ELISA. The results revealed
that the supernatant did not induce apoptosis in the uninfected macrophages at any
timepoint (Fig. 5) (Kelly et al., 2008).

FIG. 5 Soluble factors released from infected apoptotic human macrophages do not induce apoptosis in
uninfected bystander macrophages. Adapted from Kelly et al., 2008

In a final attempt to determine the cause of bystander apoptosis, the uninfected
macrophages were labeled with PKH67, a green fluorescent dye that gets incorporated
into the lipid regions of the plasma membrane, and added to infected macrophages. The
cells were co-incubated for 24 and 48h then stained using TUNEL TMR (red) to
determine if cell-cell contact was required for bystander apoptosis to occur. Bystander
macrophages undergoing apoptosis were labeled with red-green stains, showing an
increase in the level of bystander apoptosis in uninfected macrophages (Fig. 6).
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FIG. 6 Cell-cell contact between infected and uninfected macrophages induces bystander apoptosis.
Adapted from Kelly et al., 2008

The results from the experiment showed that cell-cell contact between the infected and
uninfected macrophages induced significant bystander apoptosis. Bystander apoptosis
may be a mechanism used by the innate immune response to mediate the killing of
uninfected potential niche cells, an occurrence that may serve as a way to control and
limit the progression of Mycobacterium tuberculosis infection (Kelly et al., 2008).
Inducible Nitric Oxide Synthase (iNOS) and Nitric Oxide (NO.)
Reactive nitrogen intermediates (RNIs) are antimicrobial agents formed by
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macrophages (as reviewed by Miller et al., 2004). RNIs are produced by inducible nitric
oxide synthase (iNOS) and gives rise to NO. (Miller et al., 2004). NO. is one of the few
bactericidal agents produced in vivo that is capable of successfully killing Mycobacterium
tuberculosis. NO. is a highly active free radical that is both lipid and water soluble and
has the ability to react with oxygen and oxygen intermediates to yield mycobactericidal
products such as NO 2 , NO 2 -, NO 3 -, N 2 O 3 , and ONOO- (as reviewed by Davis et al.,
2007).
Determination of iNOS Recruitment to Phagosomes with the Use of Latex Beads
Mycobacterium tuberculosis has the ability to disrupt iNOS recruitment to
phagosomes (Davis et al., 2007; Miller et al., 2004). In testing the recruitment of iNOS
to phagosomes, it is important that the alveolar macrophages are stimulated and ready to
battle infection. In studies conducted by Davis et al. (2007) and Miller et al. (2004)
alveolar macrophages were stimulated with IFN-γ and lipopolysaccharide (LPS) prior to
infection with mycobacteria. In the study conducted by Miller et al. (2004) mouse
macrophages were infected with IgG coated latex beads and incubated with polyclonal
rabbit anti-iNOS antibody. Using immunofluorescence microscopy, the intracellular
recruitment of iNOS to phagosomes infected with mycobacteria was examined. The
results revealed that the latex bead phagosomes recruited iNOS, while iNOS recruitment
to mycobacterial phagosomes did not occur because of the mycobacteria (Fig. 7) (Miller
et al., 2004 ).
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FIG. 7 Latex bead phagosomes recruit iNOS but phagosomes containing mycobacteria do not. J774
macrophages (A and B). Bone marrow-derived macrophages (C and D). Adapted from Miller et al.,
2004

Using immunofluorescence laser scanning confocal microscopy, Davis et al. (2007)
compared iNOS recruitment of phagosomes containing live mycobacteria to that of
phagosomes containing heat-killed mycobacteria. The results revealed that phagosomes
containing live mycobacteria had a reduction in iNOS recruitment when compared to
latex bead phagosomes, while phagosomes containing heat-killed mycobacteria had no
effect on iNOS recruitment to phagosomes (Fig. 8). Taken together, these results suggest
that recruitment of iNOS to mycobacteria containing phagosomes is only inhibited in
alveolar macrophages harboring live mycobacteria (Davis et al., 2007).
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FIG. 8 Live mycobacteria reduces iNOS recruitment to phagosomes. (A) Localization of iNOS
(green/red) to the phagosome for latex beads (red) and dead mycobacterial phagosomes (red), but not in
live mycobacterial phagosomes (green). (B) iNOS localization to phagosomes in macrophages infected
with latex beads, live, or dead mycobacteria. Adapted from Davis et al., 2007

The Actin Cytoskeleton and iNOS Recruitment
It was once believed that iNOS was diffusely distributed in the cytosol of
phagosomes but recently it has been recognized that iNOS recruitment to phagosomes
within alveolar macrophages requires a functional actin cytoskeleton. Ezrin-radixinmoesin (ERM)-binding phopshoprotein 50 (EBP50) is a protein that belongs to a family
of membrane-cytoskeleton linking proteins. EBP50 interacts with the CD44 glycoprotein
located at the actin filament-plasma membrane interaction site. The interaction of EBP50
with CD44 allows EBP50 to anchor different proteins to the actin cytoskeleton. Activated
mouse alveolar macrophages transfected with GFP-labeled EBP50 were infected with
Texas-Red-labeled latex beads and stained for iNOS. Using fluorescence microscopy,
the localization of iNOS to the latex bead phagosomes was analyzed. The results from
the experiment showed an increase in iNOS recruitment to the latex bead phagosomes.
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However, when the mouse macrophages were transfected with a short interfering RNA
(siRNA) sequence directed against EBP50, iNOS recruitment to the latex bead
phagosomes decreased. These findings show that EBP50 is in fact required for iNOS
recruitment to phagosomes (Fig. 9) (Davis et al., 2007).

FIG. 9 EBP50 is required for iNOS recruitment to latex bead phagosomes. (B) iNOS recruitment using
EBP50. (D) iNOS recruitment using EBP50 siRNA. Adapted from Davis et al., 2007

Coronin-1 is an actin-associated protein that functions in the rearrangement of actin.
Coronin-1 is important for cell motility and phagocytosis. Mouse macrophages
transfected with coronin-1 siRNA and incubated with Alexa 568-labeled latex beads
showed a significant increase in iNOS recruitment to the LB phagosomes (Fig. 10)
(Davis et al., 2007).
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FIG. 10 siRNA against coronin-1 increases iNOS recruitment to latex bead phagosomes. Adapted from
Davis et al., 2007

Miller et al. (2004) utilized the actin microfilament disrupter cytochalasin D and the
actin microfilament stabilizer, jasplakinolide, to show that they cause a decrease in iNOS
recruitment to latex bead phagosomes. Cytochalasin D is a membrane permeable peptide
that has the ability to bind to actin filaments and prevent their polymerization and
elongation. Jasplakinolide is a membrane permeable peptide that participates in actin
polymerization and actin filament stabilization. When cytochalasin D treatment was
followed by jasplakinolide, iNOS recruitment to latex bead phagosomes was comparable
to the control (Fig. 11) (Miller et al., 2004).

FIG. 11 A functional actin cytoskeleton is necessary for iNOS recruitment to phagosomes. Adapted from
Miller et al., 2004

Taken together, these findings clearly suggest that interfering with actin microfilament
motility can disrupt the recruitment of iNOS to latex bead phagosomes and that it is
necessary to have a functional actin cytoskeleton in order to ensure iNOS recruitment to
phagosomes (Miller et al., 2004).
Taking their experiment a step further, Davis et al. (2007) performed immunofluorescence laser scanning confocal microscopy to test iNOS recruitment to
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mycobacterial phagosomes using EBP50 and coronin-1. Macrophages transfected with
siRNA against EBP50 followed by phagocytosis of Alexa-568 labeled dead mycobacteria
showed a decrease in iNOS recruitment, demonstrating that a mutation in EBP50 alters
iNOS recruitment to mycobacteria- infected alveolar macrophages (Fig. 12).

FIG. 12 Mutations in EBP50 alters iNOS recruitment to mycobacteria-infected phagosomes. Adapted
from Davis et al., 2007

When macrophages were transfected with a siRNA against coronin-1 and incubated with
Alexa-568 labeled live mycobacteria, no effect on iNOS recruitment to phagosomes
containing live mycobacteria was observed (Fig. 13).
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FIG. 13 Mutations in coronin-1does not increase iNOS recruitment to mycobacteria-infected phagosomes.
Adapted from Davis et al., 2007

This finding shows that coronin-1 has no role in mycobacteria-induced inhibition of
iNOS recruitment to mycobacteria-infected phagosomes (Davis et al., 2007).
Mouse Model of iNOS Recruitment
Variability in the sensitivity of different Mycobacterium tuberculosis strains is
hypothesized to affect the ability of RNIs to limit the growth and replication of
Mycobacterium tuberculosis (Scanga et al., 2001). To test this possibility, three
anonymous clinical isolates of Mycobacterium tuberculosis from patients harboring
active infection and the laboratory Mycobacterium tuberculosis Erdman strain were used
to test the importance of iNOS-mediated effector functions. C57BL/6 mice and iNOS
gene-disrupted mice (NOS2-/-) were infected either intravenously or with aerosol
containing the different Mycobacterium tuberculosis strains. The results showed the
three clinical strains and Erdman strain growing at a higher rate in the NOS2-/- mice
following intravenous infection than in the C57BL/6 wild-type mice (Fig. 14) (Scanga et
al., 2001).
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FIG. 14 NOS2-/- mice have a higher bacterial burden in the lungs following intravenous infection. NOS2-/mice (closed circles). Wild-type C57BL/6 mice (open circles) mice. Mycobacterium tuberculosis strains:
(A) Erdman (B-D) Anonomyous clinical isolates. Adapted from Scanga et al., 2001

The NOS2-/- mice also had a higher bacterial burden in their lungs following aerosol
infection with the clinical and Erdman Mycobacterium tuberculosis strains (Fig. 15)
(Scanga et al., 2001).
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FIG. 15 NOS2-/- mice have a higher bacterial burden in the lungs following aerosol infection. NOS2-/mice (closed circles). Wild-type C57BL/6 mice (open circles) mice. Mycobacterium tuberculosis strains:
(A) Erdman (B-D) Anonomyous clinical isolates. Adapted from Scanga et al., 2001

Without the ability to produce iNOS, the mice quickly succumbed to infection regardless
of the route of administration. The results from these experiments display the importance
of iNOS in controlling Mycobacterium tuberculosis infection.
To investigate the role of the adaptive immune response in host resistance to
Mycobacterium tuberculosis, C57BL/6 mice and NOS2-/- were infected with H37Rv or
H37Ra in aerosol and observed for their CD4+ and CD8+ T cell responses. The number
of infiltrating leukocytes into the lungs of both sets of mice was similar to one another at
day 14 and day 30 postinfection (Fig. 16) (Beisiegel et al., 2009).

FIG. 16 NOS2-/- mice and wild-type C57BL/6 mice have a similar amount of leukocyte infiltration.
Adapted from Beisiegel et al., 2009

Of the infiltrating leukocytes, CD4+ T cell numbers were higher than CD8+ T cell
numbers in both sets of mice (Fig. 17).
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FIG. 17 NOS2-/- mice and wild-type C57BL/6 mice have a higher number of infiltrating CD4+ T cells into
the lungs. Adapted from Beisiegel et al., 2009

Further investigation revealed that the CD4+ and CD8+ T cells predominately produced
IFN-γ and TNF-α with negligible IL-17 production (Fig. 18) (Beisiegel et al., 2009).
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FIG. 18 CD4+ and CD8+ T cells of NOS2-/- and wild-type C57BL/6 mice predominately produce IFN-γ and
TNF-α with negligible IL-17 production. Adapted from Beisiegel et al., 2009

This study shows that NOS2-/- mice are capable of mounting an adaptive immune
response comparable to wild-type control mice upon challenge with Mycobacterium
tuberculosis.
Human Study of iNOS Expression
The production of NO. by Mycobacterium tuberculosis-infected mouse alveolar
macrophages has led to the hypothesis that human Mycobacterium tuberculosis-infected
alveolar macrophages are also capable of producing NO.. Supernatant from
Mycobacterium tuberculosis-infected human alveolar macrophages showed an
accumulation of NO. that could be inhibited in a dose-dependent manner when an iNOS
inhibitor was used (Fig. 19).

FIG. 19 iNOS inhibitor can inhibit NO. production in human alveolar macrophages in a dose-dependent
manner. Adapted from Rich et al., 1997

The use of the iNOS inhibitor increased the bacterial burden in the Mycobacterium
tuberculosis-infected alveolar macrophages (Rich et al., 1997). The results from this
specific experiment demonstrate that human Mycobacterium tuberculosis-infected
32

alveolar macrophages are capable of producing NO. and that this production of NO. is
important for inhibiting the growth of Mycobacterium tuberculosis.
iNOS expression and generation of RNIs by alveolar macrophages of patients
harboring active Mycobacterium tuberculosis infection was hypothesized to be detectable
through an increased level of exhaled NO.. Wang et al. (1998) conducted a study that
measured the level of NO. exhaled by patients with active infection. Patients with active
Mycobacterium tuberculosis infection exhaled significantly higher levels of NO. than
healthy control subjects. iNOS expression by the alveolar macrophages of the
tuberculosis patients was significantly higher than the control subjects and correlated
with the level of NO. that was exhaled (Fig. 20) (Wang et al., 1998).
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FIG. 20 Increased iNOS expression by alveolar macrophages of tuberculosis patients correlates with
increased NO. exhalation. Top figure: Level of iNOS expression. Bottom figure: Concentration of exhaled
NO.;TB patients (open circles); Control subjects (closed circles). Adapted from Wang et al., 1998

Confirming these findings, BAL supernatant from the tuberculosis patients contained
levels of nitrite that was significantly higher than the nitrite levels observed in the control
subjects. Upon further investigation, cultured alveolar macrophages from tuberculosis
patients showed a spontaneous release of nitrite in culture medium at a greater extent than
that released by control subjects (Fig. 21) (Wang et al., 1998).

FIG. 21 Alveolar macrophages from tuberculosis patients show a higher release of nitrite than control
subjects. Adapted from Wang et al., 1998

Overall, the finding from this study supports the hypothesis that an increase in exhaled
NO. results from increased expression of iNOS by alveolar macrophages.
Toll-Like Receptors (TLRs)
The first step in mounting an effective host response against Mycobacterium
tuberculosis begins with innate recognition of mycobacterial products. The purpose of
the innate immune system is to mount a rapid protective response during the early phase
of infection while instructing adaptive T cell-mediated immune responses during the later
phase of infection (Medzhitov et al., 2000 as reviewed by Branger et al., 2004). TLRs
are activated immediately upon or shortly after the uptake of Mycobacterium tuberculosis
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by macrophages (Heldwein et al., 2002) which make their successful activation one of
vital importance.
The Toll-like receptor was first studied in the fruit fly, Drosophila melanogaster.
Through the study of Drosophila melanogaster TLR proteins, mammalian homologues
were discovered. The human homologue of the Drosophila melanogaster Toll protein is
Toll-like receptor 4 (TLR4). There are three features of the Toll protein that link it with
innate immunity. The first feature is its participation in antifungal responses. The second
feature is its participation in signal transduction pathways. The similarity between the
Drosophila melanogaster Toll protein and mammalian homologues is that the Drosophila
melanogaster Toll protein leads to the activation of the transcription factor Dorsal, the fly
homologue of NF-κB in mammals that signals cytokine production. The final feature
refers to the similar intracellular domains that the Drosophila Toll protein and
mammalian TLRs share (as reviewed by Means et al., 1999).
Mycobacterial Antigens Recognized by TLRs
To mount a successful response against mycobacterial infection TLRs must be
able to recognize and process mycobacterial antigens. Three common antigens known to
trigger a response in the event of Mycobacterium tuberculosis infection are 19kDa
lipoprotein, lipoarabinomannan (LAM), and soluble tuberculosis factor (STF).
19kDa Lipoprotein
19kDa lipoprotein is a bacterial lipoprotein that belongs to a group of molecules
possessing pathogen-associated molecular patterns. The pathogen-associated molecular
patterns present in this group of molecules contain molecular motifs that are found in
microorganisms, not mammalian hosts (Stenger et al., 2002). 19kDa lipoprotein is an
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antigen secreted by Mycobacterium tuberculosis and is a potent inducer of T H 1 and
cytolytic T cell responses through the induction of IL-12 (Brightbill et al., 1999). 19kDa
lipoprotein induced IL-12 release in both mouse and human macrophages. The
interaction of 19kDa lipoprotein with TLR2 shows that it is capable of inducing NO.
production in mouse macrophages (Brightbill et al., 1999).
Lipoarabinomannan (LAM)
LAM is a glycolipid found in the walls of mycobacteria and plays a key role in
triggering cytokine secretion by macrophages. LAM is a potent inducer of TNF-α in both
mouse and human macrophages (Moreno et al., 1989). LAM activates mouse
macrophages by interacting with the cell surface molecule CD14 (Means et al., 1999).
Through the interaction of LAM with CD14, an intracellular signal is generated by TLR2
to activate macrophages (Means et al., 1999).
Soluble Tuberculosis Factor (STF)
STF is a short-term-culture filtrate of Mycobacterium tuberculosis that contains
the mycobacterial glycolipid phosphatidylinositolmannan (PIM). PIM induces TNF-α
secretion by mouse macrophages. STF is similar to both 19kDa lipoprotein and LAM in
that it only interacts with TLR2, not TLR4 (Jones et al., 2001).
Role of Myeloid Differentiation Protein 88 (MyD88) in TLR Signal Transduction
Signal transduction by TLRs is necessary for carrying out an effective innate
immune response. Proper signal transduction in most TLRs require myeloid
differentiation protein 88 (MyD88) (as reviewed by Tjarnlund et al., 2006). MyD88 is an
adaptor molecule that links TLR recognition to the activation of interleukin (IL)-1/ IL-1
receptor-associated kinase (IRAK), a factor essential for Mycobacterium tuberculosis-
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induced activation of macrophages (as reviewed by van Crevel et al., 2002). Multiple
studies reviewed by Tjarnlund et al. (2006) showed that mice deficient in MyD88 failed
to generate any proinflammatory responses when stimulated through their TLRs, leaving
them highly susceptible to mycobacterial infections.
Control of Mycobacterium tuberculosis Infection by TLR2 and TLR4
TLR2 and TLR4 have both demonstrated the ability to mediate Mycobacterium
tuberculosis-induced intracellular signaling in vitro and are therefore the TLRs of interest
(Branger et al., 2004). The mouse types used for the TLR studies were the C3H/HeJ
(TLR4-defective) mouse and its control C3H/HeN (TLR4-competent) mouse as well as
the C57BL/6 (TLR2-competent) and BALB/c (CD14-competent) mouse. In a study
conducted by Reiling et al. (2002) mice deficient in CD14, TLR2, and TLR4 were
administered 100 CFU of Mycobacterium tuberculosis aerosol. All three sets of mice
contained bacterial loads in their lungs similar to those of their control mice at 105 days
postinfection (Fig. 22) (Reiling et al., 2002).

FIG. 22 TLR2 and TLR4 are not effective alone, they require aid from other innate immune components.
Control (closed circle) and deficient mice (open circle). Adapted from Reiling et al., 2002

The results showed that neither TLR2 nor TLR4 were effective in providing a significant
innate immune response by themselves but that they require aid from other innate
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immune components for a successful immune response when challenged with
Mycobacterium tuberculosis. In a study conducted by Tjarnlund et al. (2006), TLR2 and
TLR4 knockout mice and C57BL/6 wild-type mice were also infected with
Mycobacterium tuberculosis aerosol. The results showed the bacterial growth in the
lungs of both the TLR2 and TLR4 knockout mice to be significantly higher during the
early phase, 3 weeks postinfection, in comparison to the C57BL/6 wild-type mice.
However, during the later phase, 8 weeks postinfection, there were no differences
between the three groups of mice (Fig. 23) (Tjarnlund et al., 2006).

FIG. 23 TLR2/4-deficient mice display increased susceptibility to aerosol infection with Mycobacterium
tuberculosis H37Rv. Adapted from Tjarnlund et al., 2006

To test the importance of TLR4 in preventing the advancement of tuberculosis infection,
C3H/HeJ mice were administered 100 CFU aerosol of Mycobacterium tuberculosis and
observed for 250 days. All of the C3H/HeJ mice died between 160 and 200 days postinfection (Fig. 24) (Abel et al., 2002).
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FIG. 24 Reduced survival of the TLR4 mutant C3H/HeJ mice after Mycobacterium tuberculosis H37Rv
infection. Wild-type C3H/HeN mice (open circles). TLR4 mutant C3H/HeJ mice (filled circles).
Adapted from Abel et al., 2002

A similar fifteen week study conducted by Branger et al. (2004) showed similar results
when seven of twelve C3H/HeJ mice administered a 100 CFU aerosol of Mycobacterium
tuberculosis died and all of the C3H/HeN wild-type mice survived (Fig. 25). The
findings from both experiments suggest an important role for TLR4 during the later phase
of Mycobacterium tuberculosis infection.

FIG. 25 Decreased survival time of TLR4 mutant C3H/HeJ mice following aerosol infection with
Mycobacterium tuberculosis H37Rv. Adapted from Branger et al., 2004

An experiment performed by Drennan et al. (2004) spanning a 6 month period tested the
ability of TLR2-deficient mice to control Mycobacterium tuberculosis infection. The
mice were administered 100 CFU of Mycobacterium tuberculosis aerosol and survived
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the entire 6 month experimental period. This finding indicates that TLR2 has a different
way of combating Mycobacterium tuberculosis infection than the one used by TLR4.
In separate experiments, higher doses of Mycobacterium tuberculosis were
administered by aerosol to the mice to determine if an increased dose of aerosol could
further affect the function of TLRs. In a second experiment performed by Reiling et al.
(2002), a higher dose of Mycobacterium tuberculosis aerosol was administered to both
C3H/HeJ and TLR2-deficient mice. Both sets of mice were administered a 2000 CFU
inoculum of Mycobacterium tuberculosis aerosol and were monitored for 210 days. The
C3H/HeJ mice were as resistant to the high-dose Mycobacterium tuberculosis infection
as their C3H/HeN control mice while the TLR2-deficient were significantly more
susceptible to the high-dose aerosol infection than the C57BL/6 mice (Fig. 26).

FIG. 26 TLR2-deficient mice are significantly more susceptible to high dose aerosol infection than TLR4
mutant C3H/HeJ mice. Adapted from Reiling et al., 2002

When TLR2-deficicent mice were administered a 500 CFU inoculum of Mycobacterium
tuberculosis aerosol in an experiment conducted by Drennan et al. (2004), the mice began
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to die between 7 and 11 weeks postinfection and were all dead by week 22. C57BL/6
mice administered the same infectious dose remained healthy and survived the entire 10
month experimental period. Data collected from the experiment showed the number of
viable mycobacteria in the lungs of the TLR2-deficient mice to be highest between week
8 and 13 postinfection. In a 23 week study conducted by Branger et al. (2004) the same
500 CFU aerosol dose was administered to C3H/HeJ mice and all of the mice died (Fig.
27).

FIG. 27 TLR4 mutant C3H/HeJ mice are susceptible to high dose aerosol infection. Adapted from
Branger et al., 2004

Because of the differences in the survival rates between the C3H/HeJ and C3H/HeN mice
Branger et al.(2004) went a step further and conducted an experiment to determine
whether bacterial loads in the mice differed during the early phase of infection. The
lungs of both the C3H/HeJ and C3H/HeN mice were observed at 2 and 5 weeks
postinfection. At 2 weeks postinfection, the lungs of the C3H/HeJ mice contained more
viable mycobacteria than the C3H/HeN mice and at 5 weeks postinfection the lungs of
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the C3H/HeJ mice displayed a 2.8-fold increase of mycobacteria in their lungs (Fig. 28)
(Branger et al., 2004).

FIG. 28 The lungs of TLR4 mutant C3H/HeJ mice contain more viable bacteria at both 2 and 5 weeks
postinfection. Adapted from Branger et al., 2004

Histological Analyses of Mice Lacking TLR4
To gain a visual understanding of the damage done to the lungs of mice lacking
TLR4 during Mycobacterium tuberculosis infection, Branger et al. (2004) performed a
histopathological analysis of the lungs of C3H/HeJ and C3H/HeN mice at 2 and 5 weeks
following aerosol infection. At 2 weeks postinfection, the lungs of the C3H/HeN mice
displayed a slight cell infiltration consisting of macrophages, lymphocytes and
neutrophils (Fig. 29a) while the C3H/HeJ mice displayed larger areas of inflammation
(Fig. 29b) that was attributed to the higher number of leukocytes (Table 2). At 5 weeks
postinfection, inflammation was more pronounced in both the C3H/HeN and C3H/HeJ
mice. The inflammatory infiltrate of the C3H/HeN mice consumed between 50 and 60%
of their lung surface (Fig. 29c) (Table 2) and the infiltrate of the C3H/HeJ mice

42

consumed between 70 and 80% of their lung surface (Fig. 29d)

(Table 2) (Branger et

al., 2004).

FIG. 29 Histopathological analysis of the lungs of C3H/HeJ and C3H/HeN mice at 2 and 5 weeks
postinfection. (A) Wild-type lung tissue 2 weeks postinfection. (B) TLR4 mutant lung tissue 2 weeks
postinfection. (C) Wild-type mouse lungs 5 weeks postinfection. (D) TLR4 mutant lungs 5 weeks
postinfection. Adapted from Branger et al., 2004

TABLE 2 Cell subsets in the left lung in TLR4 mutant and wild-type mice during pulmonary
tuberculosis. Adapted from Branger et al., 2004

Abel et al. (2002) also studied the inflammatory responses in the lungs of C3H/HeJ and
C3H/HeN mice exposed to Mycobacterium tuberculosis aerosol. Microscopy of the
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lungs of both the C3H/HeJ and C3H/HeN mice 28 days postinfection showed the
formation of small granulomas (Fig. 30a; Fig. 30b). At 140 days postinfection the
C3H/HeJ mice had massive inflammation in their lungs with large numbers of
macrophages and neutrophils consuming majority of the airspace (Fig. 30d) while the
C3H/HeN mice did not (Fig. 30c) (Abel et al., 2002).

FIG. 30 The inflammatory responses in the lungs of both C3H/HeJ and C3H/HeN mice exposed to
Mycobacterium tuberculosis aerosol. (A) C3H/HeN and (B) C3H/HeJ mice 28 days following aerosol
infection. (C) C3H/HeN and (D) C3H/HeJ mice 140 days following aerosol infection. Adapted from
Abel et al., 2002

To further investigate the inflammatory cells recruited to the lungs of the mice during the
inflammatory response, BAL was performed 4 weeks following aerosol infection with
Mycobacterium tuberculosis. The results showed comparable total cell counts for the
two groups of mice, however the C3H/HeN mice had a significantly larger proportion of
macrophages present than the C3H/HeJ mice (Fig. 31a). Besides the number of
macrophages present in the two groups of mice, the lymphocyte population was also
comparable (Fig. 31b). BAL analysis showed a significant number of neutrophils being
recruited to the lungs of the C3H/HeJ mice but not the C3H/HeN mice (Fig. 31c). The
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data obtained from this experiment support the histological findings of reduced
macrophage but significant neutrophil recruitment to the lungs of C3H/HeJ mice
harboring Mycobacterium tuberculosis infection (Abel et al., 2002).

FIG. 31 Decreased macrophage and increased neutrophil recruitment into the lungs of TLR4 mutant
C3H/HeJ mice 4 weeks postinfection. Adapted from Abel et al., 2002

TLR2- and TLR4-Mediated Cytokine Production
After observing how a lack of TLR2 and/or TLR4 could affect cell recruitment to
the lungs of Mycobacterium tuberculosis-infected mice, Reiling et al. (2002) compared
the production of IL-12 in TLR2-deficient and C3H/HeJ mice in a 10 day study to
determine if a lack in cell recruitment placed a damper on important cytokine production.
There were no significant differences observed in IL-12 production between the C3H/HeJ
and C3H/HeN mice at day 0 or day 10 postinfection (Fig. 32a). The TLR2-deficient
mice however showed a significant decrease in the IL-12 production in comparison to
C57BL/6 mice at day 10 (Fig. 32b). This difference in IL-12 production at day 10 is
hypothesized to be responsible for the TLR2-deficient mices’ higher susceptibility to
Mycobacterium tuberculosis infection and decreased proinflammatory response (Reiling
et al., 2002).
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FIG. 32 IL-12 production in C3H/HeJ and TLR2-deficient mice following high-dose aerosol infection with
Mycobacterium tuberculosis. Adapted from Reiling et al., 2002

Abel et al. (2002) also conducted an experiment to observe cytokine production in the
lungs of C3H/HeJ mice following Mycobacterium tuberculosis infection. At 4 weeks
postinfection, BAL fluid of C3H/HeJ mice was assessed using ELISA. The results
showed a significant reduction in IL-12 production (Fig. 33a) while TNF-α and IFN-γ
production remained steady (Fig. 33b; Fig. 33c).

FIG. 33 Decreased IL-12 production in BAL fluid of TLR4 mutant C3H/NeJ mice following
Mycobacterium tuberculosis infection. (A) IL-12p40, (B) IFN-γ, (C) TNF-α. Adapted from Abel et al.,
2002
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To further assess cytokine production in the C3H/HeJ mice, the infected lungs were
homogenized and the supernatants were analyzed. The results once again showed a
significant reduction in both IL-12 and TNF-α (Fig. 34a; Fig. 34c) while the level of IFNγ was only slightly lower than the C3H/HeN mice (Fig. 34b). The results from this study
suggest that the reduction in proinflammatory cytokines upon Mycobacterium
tuberculosis infection is associated with an increased susceptibility to Mycobacterium
tuberculosis infection (Abel et al., 2002).

FIG. 34 Decreased cytokine levels in the lungs of TLR4 mutant C3H/HeJ mice. (A) IL-12, (B) IFN-γ, (C)
TNF-α. Adapted from Abel et al., 2002

IFN-γ production in C3H/HeJ mice following aerosol infection with Mycobacterium
tuberculosis displayed similar IFN-γ levels to C3H/HeN mice at 2 weeks postinfection.
At 5 weeks postinfection, however, IFN-γ levels in the C3H/HeJ mice were elevated (Fig.
35), coinciding with the increased mycobacterial load observed in their lungs (Branger et
al., 2004).
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FIG. 35 IFN-γ concentrations in lungs of TLR4 mutant C3H/HeJ and wild-type mice following aerosol
infection with Mycobacterium tuberculosis. Adapted from Branger et al., 2004

In the case of TLR2 and TLR4 knockout mice, mRNA expression of both IFN-γ and
TNF-α were the same as the wild-type mice at both 3 and 8 weeks postinfection
(Tjarnlund et al., 2006).
Gamma Delta (γδ) T Cells
γδ and CD4+ cells are the two dominant T cell subsets found in the human
immune response to Mycobacterium tuberculosis that contribute to the proinflammatory
responses involved in protective immunity (Tsukaguchi et al., 1999). In normal healthy
individuals, there are more Mycobacterium tuberculosis-reactive γδ T cells than αβ T
cells. All γδ T cells express a TCR encoded by a single Vγ9 and Vδ2 gene (as reviewed
by Li et al., 1998) and studies have shown that γδ T cells are the main source of IFN-γ
production (Tsukaguchi et al., 1999). Li et al. (1998) showed that patients harboring
active tuberculosis infection have a significantly reduced number of Mycobacterium
tuberculosis-reactive γδ T cells in their blood and BAL in comparison to normal healthy
individuals. This finding may explain the progression and severity of Mycobacterium
tuberculosis disease. The loss or absence of γδ T cells in tuberculosis patients may
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reflect anergy, inactivation or dysfunction of immune cell populations necessary for γδ T
cell activation and growth, or activation-induced cell death (AICD) (as reviewed by Li et
al., 1998).
Effect of Drug Chemotherapy on γδ T Cell Numbers
As drug treatment for patients harboring active Mycobacterium tuberculosis
infection evolves, a question of whether or not drug chemotherapy is responsible for the
decreased numbers of Mycobacterium tuberculosis-reactive γδ T cells in tuberculosis
patients remains unclear. In an attempt to determine if drug chemotherapy adversely
affects γδ T cells or has a beneficial effect on γδ T cell numbers, Li et al. (1998)
conducted an experiment to analyze the number of peripheral γδ T cells during and after
drug chemotherapy. The results from the study showed a significant reduction in the γδ
T cell numbers of non-treated active disease patients in comparison to the γδ T cell
numbers of non-treated normal patients. Non-treated patients with inactive (latent)
disease showed a slight decrease in their γδ T cell numbers in comparison to non-treated
normal patients but showed a significant increase in their γδ T cell numbers in
comparison to non-treated patients with active disease (Fig. 36) (Li et al., 1998).
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FIG. 36 Tuberculosis patients with active disease have reduced numbers of Mycobacterium tuberculosisreactive γδ T cells. Adapted from Li et al., 1998

All of the active and inactive disease patients and normal patients undergoing drug
treatment were followed for a period of time spanning from 2 to 16 months. The treated
active disease patients had a decrease in their γδ T cell numbers despite the length of
treatment. γδ T cell numbers were recovered in the treated inactive (latent) disease
patients (Fig. 36). Based on the results received from the treated groups of patients, it
was concluded that drug chemotherapy treatment for Mycobacterium tuberculosis was
not responsible for the loss of γδ T cell numbers in patients harboring active
Mycobacterium tuberculosis infection (Li et al., 1998).

γδ T Cells vs. CD4+ T Cells: IFN-γ Production
γδ T cells and CD4+ T cells produce IFN-γ and serve as cytotoxic effector cells in
response to Mycobacterium tuberculosis-infected macrophages. To test IFN-γ production
by γδ T cells and CD4+ T cells in response to Mycobacterium tuberculosis infection,
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supernatant from human PMBCs were stimulated with either Mycobacterium
tuberculosis or PPD and analyzed using ELISA and ELISPOT. CD4+ T cells produced
IFN-γ in response to PPD and Mycobacterium tuberculosis, while γδ T cells produced
IFN-γ in response to Mycobacterium tuberculosis only (Fig. 37) (Tsukaguchi et al.,
1999). The findings from this experiment suggest that CD4+ T cells and γδ T cells differ
in the mycobacterial antigens that they recognize. Findings from the experiment also
suggest that γδ T cells are capable of producing more IFN-γ on a per cell basis than CD4+
T cells in response to tubercle bacilli (Fig. 37) (Tsukaguchi et al., 1999).

FIG. 37 Comparison of IFN-γ production by CD4+ and γδ T cells in response to Mycobacterium
tuberculosis. Adapted from Tskaguchi et al., 1999

TNF-α plays a role in protective immunity against mycobacterial infections in both mice
and humans (as reviewed by Tsukaguchi et al., 1999). To determine the role of γδ T cells
and CD4+ T cells in TNF-α production, the supernatant from Mycobacterium
tuberculosis-infected human monocytes in both the presence and absence of γδ T cells
and CD4+ T cells was analyzed using ELISA. Results from the experiment revealed that
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TNF-α is increased in the presence of γδ T cells and CD4+ T cells (Tsukaguchi et al.,
1999).
Influence of NK Cells on γδ T Cell Numbers
NK cells are effective regulators of the innate and adaptive immune responses.
The participation of NK cells in the early immune response to intracellular pathogens has
been recognized. NK cells are capable of direct cell lysis, IFN-γ production, and
initiation of apoptosis (as reviewed by Brill et al., 2001). Isolated human NK cells added
to Mycobacterium tuberculosis-infected monocytes mediated the killing of intracellular
tubercle bacilli within 24h of coculture (Brill et al., 2001), demonstrating the effector
function of this cell type. Because the relationship between NK and γδ T cell numbers in
active tuberculosis infection has not been studied, Zhang et al. (2006) hypothesized that
NK cells might be involved in the immune regulation of γδ T cells in response to
Mycobacterium tuberculosis and that the loss of γδ T cells may be due to a decrease in
NK cell activity. To investigate the role of NK cells in the immune response of γδ T cells
to Mycobacterium tuberculosis infection, heat-treated antigens from Mycobacterium
tuberculosis were used to expand γδ T cells in vitro. Results from the experiment
showed that γδ T cells proliferate faster in a high NK cell-percentage population than in a
low NK cell-percentage population (Fig. 38) (Zhang et al., 2006).
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Culture days
FIG. 38 γδ T cells proliferate faster in a high NK cell-percentage population. Adapted from Zhang et al.,
2006

This finding suggests that NK cell numbers affect the proliferation response of γδ T cells

and that in the event of NK cell depletion, γδ T cell proliferation would decrease (Zhang
et al., 2006).
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THE ADAPTIVE IMMUNE RESPONSE AGAINST MYCOBACTERIUM
TUBERCULOSIS
Inter leukin 17 (IL-17)
IL-17 is a potent inflammatory cytokine secreted by T lymphocytes such as Th17
and CD4+ T cells (as reviewed by Peng et al., 2008). IL-17 induces chemokine
production and augments neutrophil accumulation (as reviewed by Lockhart et al., 2006).
The production of IL-17 by Th17 cells is regulated by IFN-γ. It is hypothesized that IFNγ and IL-17 have the ability to counterregulate each other during chronic mycobacterial
infections (Cruz et al., 2006).
IL-17-Producing Cells
In a study to investigate the source of IL-17 in tuberculosis patients, the
proportion of IL-17-producing cells in their peripheral blood was measured. γδ T cells
were the main source of IL-17, with other IL-17-producing cells making up a small
proportion of the peripheral blood lymphocytes. The overall percentage of IL-17producing cells in the peripheral blood of the tuberculosis patients and healthy donors
was very similar (Fig. 39b), however the percentage of IL-17-producing γδ T cells was
significantly higher in tuberculosis patients (Fig. 39c) (Peng et al., 2008).
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FIG. 39 The percentage of IL-17- producing γδ T cells is significantly higher in tuberculosis patients. (B)
The percentages for IL-17+ cells of lymphocytes. (C) The percentages for CD3+ cells and γδ T cells among
IL-17+ cells. Adapted from Peng et al., 2008

Purified cells from the lungs of Mycobacterium tuberculosis-infected mice at 2, 4, and 52
weeks postinfection were studied. The purified cells were fractioned into three groups.
Group 1 consisted of CD4+ and CD8+ T cells, B cells, and macrophages (“CD4 pool”).
Group 2 was composed of γδ T cells. Group 3 consisted of NK cells, NK T cells, and
other cell types (“flow through”). Each cell group was stimulated with supernatant from
Mycobacterium tuberculosis-infected dendritic cells for 48h and tested for IL-17
production using ELISPOT. The results showed that the γδ T cells and “flow through”
fractions were capable of producing IL-17 at all three time points at a higher level than
the “CD4 pool” (Fig. 40) (Lockhart et al., 2006).
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FIG. 40 γδ and other non-CD4 T cells contribute to IL-17 production in Mycobacterium tuberculosisinfected mice. (B) Lungs at 2 weeks postinfection, (C) Lungs at 4 weeks postinfection, (D) Lungs at 52
weeks postinfection. Adapted from Lockhart et al., 2006

The results obtained from this particular experiment show that γδ T cells and other nonCD4+ or CD8+ T cells are capable of producing IL-17 during Mycobacterium
tuberculosis infection and that γδ T cells produce more IL-17 than CD4+ T cells
(Lockhart et al., 2006).
Counterregulation of IL-17 and IFN-γ
IFN-γ regulates IL-17 production both in vitro and in vivo (as reviewed by Cruz et
al., 2006). In an experiment using C57BL/6 and IFN-γ-deficient mice, IFN-γ production
was tested to see if it could limit IL-17 T cell responses to BCG. The C57BL/6 and IFNγ-deficient mice were intravenously infected with BCG and the expansion of IL-17producing CD4+ T cells was observed. The IFN-γ-deficient mice produced more IL-17
than the C57BL/6 mice at both 15 and 21 days postinfection (Fig. 41). This finding
supports the hypothesis that IFN-γ regulates the IL-17 response (Cruz et al., 2006).
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FIG. 41 IFN-γ-deficient mice produce more IL-17 than wild-type C57BL/6 mice following BCG infection.
C57BL/6 mice (shaded bar). IFN-γ-deficient mice (striped bar). Adapted from Cruz et al., 2006

In an experiment conducted by Peng et al. (2008) the percentage of IFN-γ-producing γδ
T cells in the peripheral blood of tuberculosis patients was significantly lower than
healthy donors while the percentage of IL-17-producing γδ T cells was significantly
higher in the tuberculosis patients (Fig. 42b). Further testing showed the ratio of IFN-γproducing γδ T cells to IL-17-producing γδ T cells in the peripheral blood of tuberculosis
patients to be significantly lower than those of the healthy donors (Fig. 42c). This
finding confirms that IL-17-producing γδ T cells are increased in tuberculosis patients
(Peng et al., 2008).

FIG. 42 IL-17-producing γδ T cells are increased in the peripheral blood of tuberculosis patients.
Adapted from Peng et al., 2008

The findings from these experiments support the hypothesis that an inability of
tuberculosis patients to produce enough IFN-γ to dampen IL-17-mediated inflammation
during chronic Mycobacterium tuberculosis infection predisposes them to inappropriate
tissue-damaging responses (Cruz et al., 2006).
CD4+ and CD8+ T Cells
The protective immune response against Mycobacterium tuberculosis relies on
cell mediated immunity. Mycobacterium tuberculosis is a pathogen that primarily resides
within cells, usually macrophages. Because of the survival method used by
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Mycobacterium tuberculosis, T cell effector mechanisms rather than antibodies are
required to control and/or eliminate the bacteria (Flynn et al., 2001). It is the interaction
between infected macrophages and T cells that defines the successful elimination of
Mycobacterium tuberculosis from an infected individual (van Crevel et al., 2002). A
proper protective immune response mounted against Mycobacterium tuberculosis occurs
in a series of steps. First, the bacteria are delivered by resident and/or recruited APCs to
secondary lymphoid tissues. Second, the APCs migrate to regions of the secondary
lymphoid tissues that are enriched in naïve CD4+ and CD8+ T cells that become activated.
Third, the activated CD4+ and CD8+ T cells migrate via the bloodstream to the site/s of
infection. Lastly, the CD4+ and CD8+ T cells emigrate from the intravascular space into
the tissue where they either deliver macrophage-activating cytokines or kill the infected
cells by direct contact (Peters et al., 2003).
CD8+ T Cell Response to Mycobacterium tuberculosis Infection
At one time research focused primarily on CD4+ T cell responses to
Mycobacterium tuberculosis infection. Studies have shown CD4+ T cells to be two-fold
more abundant than CD8+ T cells at sites of tuberculosis infection in both mice and
humans (as reviewed by Peters et al., 2003). Recently, more interest has been placed into
the role that CD8+ T cells have in mounting an immune response against Mycobacterium
tuberculosis infection. Serbina et al. (2001) reported that the percentage of CD8+ T cells
in Mycobacterium tuberculosis-infected lungs of CD4+ T cell-deficient mice was twofold higher than in the lungs of wild-type mice following aerosol infection (Fig. 44).
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FIG. 43 CD4+ T cell-deficient mice have more CD8+ T cells in their lungs than wild-type mice following
Mycobacterium tuberculosis infection. Wild-type mice(open square). CD4+ T cell-deficient mice (closed
square). Adapted from Serbina et al., 2001

Direct lysis and IFN-γ production are two effector functions used by CD8+ T cells (Flynn
et al., 2001) and CD4+ T cells are important for the maintenance of CD8+ T cell effector
functions (Serbina et al., 2001). So despite the increase in the number of CD8+ T cells,
further investigation revealed significant reductions in the specific lysis mediated by the
cytotoxic CD8+ T cells in the lungs of CD4+ T cell-deficient mice (Fig. 45)

FIG. 44 Lysis mediated by cytotoxic CD8+ T cells is reduced in the lungs of CD4+ T cell-deficient mice.
Wild-type mice (squares). CD4+ T cell-deficient mice (circles). Adapted from Serbina et al., 2001

(Serbina et al., 2001). The results from the two experiments conducted by Serbina et al.
(2001) suggest that the cytotoxic activity of Mycobacterium tuberculosis-specific
cytotoxic CD8+ T cells is compromised in the absence of CD4+ T cells.
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Based on the newfound information pertaining to the role that CD8+ T cells have
in combating Mycobacterium tuberculosis infection in the mouse model, Carranza et al.
(2006) analyzed the role of this specific T cell subset in individuals harboring active
Mycobacterium tuberculosis disease. To test if exposure to Mycobacterium tuberculosis
aerosol induced bactericidal activity mediated by T cells, autologous blood CD8+ and
CD4+ T cells from healthy individuals were added to attenuated H 37 Ra and virulent
H 37 Rv Mycobacterium tuberculosis-infected alveolar macrophages. The H 37 Ra and
H 37 Rv Mycobacterium tuberculosis-infected cultures both controlled the growth of the
tubercle bacilli when the alveolar macrophages were cocultured with CD8+ T cells (Fig.
46) (Carranza et al., 2006).

FIG. 45 Both H37Ra- and H37Rv-infected alveolar macrophage cultures control the growth of tubercle
bacilli when cocultured with CD8+ T cells. Alveolar macrophages alone (closed circles). Alveolar
macrophage/ CD8 coculture (open circles). Adapted from Carranza et al., 2006

This finding further supports the participation of CD8+ T cells in the immune response
against Mycobacterium tuberculosis infection.
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IFN-γ Production by CD8+ T Cells
To test the influence that CD8+ T cells had on the production of IFN-γ, alveolar
macrophage cultures and alveolar macrophage/CD8+ T cell cocultures of healthy
individuals were infected with the H 37 Ra or H 37 Rv Mycobacterium tuberculosis strains
for one week. Both strains caused an increase in IFN-γ concentration from day 0 to day
7. The H 37 Rv-infected alveolar macrophage cultures and alveolar macrophage/CD8+ T
cell cocultures displayed IFN-γ concentrations that were two-three times higher than the
H 37 Ra strain. However, IFN-γ concentrations of the alveolar macrophage/CD8+ T cell
cocultures were one- to four times higher than the alveolar macrophage cultures of both
strains (Fig. 47) (Carranza et al., 2006).

FIG. 46 IFN-γ production in alveolar macrophage/CD8+ T cell cocultures is significantly higher than
alveolar macrophage cultures alone. Alveolar macrophages alone (black bars). Alveolar macrophage/CD8
coculture (white bars). Adapted from Carranza et al., 2006

The results show that CD8+ T cells are capable of inhibiting Mycobacterium tuberculosis
growth and producing IFN-γ, two elements necessary in combating tuberculosis. To
compare the amount of IFN-γ produced by CD8+ T cells to that produced by CD4+ T
61

cells, the same experiment was performed except that alveolar macrophage/CD4+ T cell
cocultures were used in place of alveolar macrophage/CD8+ T cell cocultures. Similar to
the results given when studying CD8+ T cells, the IFN-γ concentrations were higher in
the alveolar macrophage/CD4+ T cell cocultures than in the alveolar macrophage cultures
alone (Fig. 48) (Carranza et al., 2006).

FIG. 47 IFN-γ concentrations are higher in alveolar macrophage/CD4+ T cell cocultures than alveolar
macrophages alone. Alveolar macrophages alone (black circles). Alveolar macrophage/ CD4 coculture
(white circles). IFN-γ production in alveolar macrophages alone (black bars). IFN-γ production in alveolar
macrophages/CD4 coculture (gray bars). Adapted from Carranza et al., 2006

Overall, it was shown that IFN-γ levels of the alveolar macrophage/CD4+ T cell
cocultures were higher than those of the alveolar macrophage/CD8+ T cell cocultures
regardless of the Mycobacterium tuberculosis strain used. The findings from these two
experiments suggest that Mycobacterium tuberculosis antigen-specific human CD4+ T
cells are the primary source of IFN-γ and that CD8+ T cells although less than CD4+ T
cells, do contribute to IFN-γ production in the event of Mycobacterium tuberculosis
infection (Carranza et al., 2006).
IFN-γ Production by CD4+ T Cells
To take a closer look at the role of CD4+ T cells in Mycobacterium tuberculosis,
Caruso et al. (1999) performed a study involving wild-type, MHC II-deficient, and CD4+
T cell-deficient mice. The results from their experiment showed all three groups of mice
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producing low levels of IFN-γ one week postinfection while at two weeks postinfection
IFN-γ production in the MHC II-deficient and CD4+ T cell-deficient mice was only 44%
of that in the wild-type mice. It was not until four weeks postinfection that the total
amount of IFN-γ within the lungs of the wild-type and CD4+ T cell-deficient mice was
similar (Fig. 49) (Caruso et al., 1999).

FIG. 48 IFN-γ production in lung cells from Mycobacterium tuberculosis-infected mice. Wild-type mice
(open square). MHC II-deficient mice (closed circle). CD4+ T cell-deficient mice (closed triangle).
Adapted from Caruso et al., 1999

Further analysis uncovered that IFN-γ production by CD8+ T cells in the CD4+ T celldeficient and wild-type mice was the same at two weeks postinfection but that the
contribution of CD4+ T cells to IFN-γ production was absent in the MHC II-deficient and
CD4+ T cell-deficient mice (Caruso et al., 1999). It is hypothesized that the absence of
CD4+ T cells in MHC II-deficient and CD4+ T cell-deficient mice may be responsible for
preventing CD8+ T cells from becoming cytotoxic, an occurrence that may contribute to
MHC II-deficient and CD4+ T cell-deficient mice being more susceptible to
Mycobacterium tuberculosis infection. The findings from this experiment suggest that
IFN-γ production by CD4+ T cells is needed to have an effective immune response early
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in Mycobacterium tuberculosis infection and that IFN-γ production by CD8+ T cells is
insufficient to control infection on its own (Caruso et al., 1999).
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DRUG TREATMENT FOR MYCOBACTERIUM TUBERCULOSIS
As more knowledge and understanding about how Mycobacterium tuberculosis is
recognized and controlled by the immune system surfaces, the development of effective
vaccines remains an important goal in controlling tuberculosis infection. Vaccination is
still the best hope for ultimately eradicating this disease (Schluger, 2001), however, there
are challenges in attempts to design and develop successful vaccines to fight against
Mycobacterium tuberculosis infection. The pathogenesis of tuberculosis infection is
studied in animal models and there is no completely satisfactory animal model of human
tuberculosis available (Schluger, 2001). This presents a challenge because animal
models permit the study of the risk of actual tuberculosis infection whereas human
studies focus on the progression of tuberculosis infection to active disease in patients
harboring latent infection (Schluger, 2001).
Although there is no perfect animal model for the study of Mycobacterium
tuberculosis in humans, animal studies have the potential to provide useful information
about Mycobacterium tuberculosis infection. Various animal hosts (Table 3) have been
used for tuberculosis studies but the expense of some of the animals and the cost of
keeping them under level III biosafety conditions has made the mouse the model of
choice (Orme, 2005).
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TABLE 3 Overview of animal models for vaccine testing. Adapted from Orme, 2005

Vaccine testing in the mouse model occurs in a series of steps. First the mice are
vaccinated against Mycobacterium tuberculosis then infected with virulent
Mycobacterium tuberculosis a few weeks later. Following infection with Mycobacterium
tuberculosis the mice are screened at various time points and at 30 days postinfection are
tested for the bacterial load in their lungs and other organs such as the spleen and liver.
The bacterial loads of the infected mice are then compared to those of the uninfected
control mice (Orme, 2005). The results produced in these studies allow for identification
and evaluation of vaccine longevity and effectiveness as well as the degree to which the
mice are able to generate both a T H 1-type CD4+ and CD8+ T cell response (Orme, 2005).
Vaccines
In designing an effective vaccine against Mycobacterium tuberculosis infection it
is important for the vaccine to possess certain qualities. An effective vaccine should be
able to induce a good immune response. The vaccine should consist of molecules that are
foreign to the host and complex, demonstrating stability and degradability so that the
antigenic material gets processed and presented to lymphocytes (Sable et al., 2007). In
searching for good vaccine candidates it is ideal for the vaccine to be safe and
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inexpensive, provide full protection after a single administration, provide worldwide
protection against disease and infection, induce lifelong immunological memory, and not
compromise the tuberculin skin tests (TSTs) (Andersen, 2001).
Recombinant Bacillus Calmette-Guerin (BCG)
The recombinant Bacillus Calmette-Guerin (BCG) vaccine, originally developed
from Mycobacterium bovis, was designed nearly a century ago. BCG is considered to be
a safe cost effective option for vaccinating against Mycobacterium tuberculosis infection
(Orme, 2005). However, multiple BCG vaccine trials carried out in different countries
have shown this vaccine to be variable in its degree of protection against Mycobacterium
tuberculosis infection. BCG possesses an effectiveness ranging from 0-80% and its
efficacy is believed to wane with time, remaining protective for only 10-20 years (as
reviewed by Sable et al., 2007). Studies have shown that tuberculin reactivity following
BCG vaccination depends on the age of administration. Administration of the BCG
vaccine during infancy has been shown to be highly effective in protecting against severe
cases of Mycobacterium tuberculosis due to the rapid waning of tuberculin reactions (as
reviewed by Menzies, 2000). BCG vaccination of individuals after the first year of life,
however, has been shown to result in persistent tuberculin reactions (as reviewed by
Menzies, 2000). It is argued that this loss of protection from childhood through young
adult life may be the reason for the increased incidence of tuberculosis infection (Sable et
al., 2007). Several reasons have been suggested for variation in the protective efficacy an
overall failure of the BCG vaccine. Variations in the effectiveness of the BCG vaccine
are believed to be either directly or indirectly related to genetic differences in vaccinated
populations, differences in BCG strains, dose and vaccination protocols, over-attenuated
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parent strains, administration of the vaccine to already sensitized or infected individuals,
and the interaction between BCG and environmental mycobacteria which can mask or
block its protective effect (as reviewed by Sable et al., 2007).
The 0-80% variable efficacy of BCG and the difficulty of improving its protection
have lead to the need for more effective tuberculosis vaccines (as reviewed by Sable et
al., 2007).

The United States and other industrialized countries with low incidences of

tuberculosis infection have discontinued the use of the BCG vaccine. BCG vaccination
has been shown to affect tuberculin skin tests (TSTs) which makes it difficult to interpret
the results (Cohn, 2001). Because there is no reliable method to distinguish between an
individual displaying a true-positive TST because of actual Mycobacterium tuberculosis
infection from an individual with a false-positive TST resulting from prior vaccination
with BCG, creating a more effective vaccine to aid in the prevention of Mycobacterium
tuberculosis is one of extreme importance (Cohn, 2001).
Culture Filtrate Protein (CFP)
In early attempts to develop effective vaccines against Mycobacterium
tuberculosis infection, heat-killed bacilli were the preparations of choice. However,
vaccines containing heat-killed tubercle bacilli only gave rise to non-specific
inflammatory responses as opposed to the long-term protection that was desired (Orme,
1988). Only mice that were immunized with live Mycobacterium tuberculosis generated
a protective T cell response over a 30 day experimental period (Orme, 1988). It is
hypothesized that the secreted proteins of Mycobacterium tuberculosis present in the
secretory or total culture filtrate protein (CFP) pools are the key protective antigens of the
tubercle bacillus responsible for the rise of the T cell-mediated host immune responses
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necessary for the control and containment of Mycobacterium tuberculosis infection
(Roberts et al., 1995). Today, the use of CFP vaccines is being explored because of their
ability to impart significant protection against tuberculosis infection in the mouse model.
Mice immunized with purified CFP antigens from the Mycobacterium tuberculosis
Erdman strain and challenged with a low-dose aerosol of Mycobacterium tuberculosis
were resistant to tuberculosis infection. Immunization with the CFP antigens generated
CD4+ T cells that secreted IFN-γ (Roberts et al., 1995), presenting the possibility for the
use CFP vaccines. However, despite findings from CFP experiments, there are two
limitations preventing CFP from being an effective vaccine. The first limitation is that
CFP provides initial protection upon infection with Mycobacterium tuberculosis, but like
BCG, the effectiveness wanes with time. The second limitation of using CFP as vaccine
is that it has to be delivered in adjuvant (Roberts et al., 1995). Another setback for the
use of CFP vaccines reside in the differences that arise with each culture condition and
the risk of the vaccine possibly possessing both protective and deleterious molecules
because of improper purification (Sable et al., 2007).
Early Secretory Antigenic Target of 6 kDa (ESAT-6)
Live vaccines can cause life-threatening disease in immunocompromised
individuals, a fact that has lead to the development of subunit vaccines. Mycobacterial
components such as proteins, lipids, and carbohydrates are screened from both secretory
and subcellular compartments to develop subunit vaccines (Sable et al., 2007). The early
secretory antigenic target of 6 kDa (ESAT-6), a secreted antigen of Mycobacterium
tuberculosis, has been shown to give a strong protective response against tuberculosis
infection (Orme, 2005). Low molecular weight polypeptides such as ESAT-6 make ideal
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vaccine candidates because of their ability to induce dominant T H 1 responses with
negligible T H 2 responses (Sable et al., 2007). In mouse macrophages ESAT-6
demonstrated the ability to enhance IFN-γ-induced accumulation of iNOS, suggesting its
participation in NO. release via macrophage stimulation (Singh et al., 2005). The strong
antigenicity of ESAT-6 is hypothesized to result from its small size, possibly rendering it
more susceptible to presentation to and processing by CD4+ T lymphocytes following its
release in the phagosome. It is also hypothesized that ESAT-6 gains access to the
cytoplasm and class-I processing machinery contained in the proteosome, leading to
strong cytotoxic T cell responses (as reviewed by Sable et al., 2007). As with other
vaccines however, vaccination with ESAT-6 has presented a problem. The problem is
that ESAT-6 has a low inherent immunogenicity and requires being complexed with
multiple strong adjuvants to mount a sufficient immune response. Mice immunized with
ESAT-6 complexed with the hydrophobic adjuvant monophosphoryl lipid A (MPL) did
not give rise to IFN-γ-producing T cells and mice immunized with ESAT-6 complexed
with dimethyl dioctadecylammonium bromide (DDA) give rise to a low number IFN-γproducing T cells. It was not until ESAT-6 was emulsified in DDA-MPL that a very high
number of IFN-γ-secreting CD4+ T cells was observed (Brandt et al., 2000). The results
from this experiment emphasizes how the use and choice of adjuvant influences the
efficacy of ESAT-6 in mounting a sufficient IFN-γ-producing T cell response.
Inhalable Microparticles
The manner in which drugs are delivered to targeted alveolar macrophages can
affect their activation (Sharma et al., 2007). Sharma et al. (2001) showed that drug
concentrations found in the serum or macrophages of mice can vary based on the route of
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administration. They observed that high serum drug concentrations did not necessarily
lead to high intracellular drug concentrations and that high intracellular drug
concentrations achieved by administering microparticles did not necessarily lead to high
serum drug concentrations (Fig. 50) (Sharma et al., 2001).

FIG. 49 The route of drug administration can affect the activation of alveolar macrophages in mice.
Adapted from Sharma et al., 2001

A proposed reason for treatment failure in the event of Mycobacterium tuberculosis
infection is that drug concentrations achieved in the cytosol of targeted cells through oral
administration are not sufficient enough to kill the bacteria residing within the
macrophages (Sharma et al., 2001).
Macrophages infected with Mycobacterium tuberculosis retain their ability to
phagocytose and process additional material (Oh et al., 1996 as reviewed by Sharma et
al., 2007). Because the role of alveolar macrophages is to uptake bacteria found in the
lungs and transport it to secondary lymphoid organs, it is possible that the bacteria could
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be exposed to, taken up by the bloodstream, and delivered to sites of macrophage
trafficking. Sharma et al. (2001) proposed that loading resident alveolar macrophages of
the lung with biodegradable drug-containing microparticles ranging in size from 0.5-3
microns would lead to transport of the drug to sites where alveolar macrophages migrate,
thus preventing the spread of Mycobacterium tuberculosis which would otherwise go
undetected. Inhaled microparticles phagocytosed by alveolar macrophages may deliver
larger amounts of drug to the cytosol than using the oral route or by dissolving the drugs
in body fluids (Sharma et al., 2001). Goals of using inhalable microparticles as opposed
to oral drug administration to battle Mycobacterium tuberculosis infection include
reducing the drug dose, reducing the dose frequency and toxicity, improving patient
compliance, and most importantly targeting specific macrophages that harbor
Mycobacterium tuberculosis (Sharma et al., 2001). The overall objective of using
inhalant microparticles to treat tuberculosis infection is to achieve high intracellular drug
concentrations in the infected macrophages (Sharma et al., 2007).
Isoniazid (H) and Rifampicin (R)
In developing an effective aerosol drug to treat Mycobacterium tuberculosis
infection, it is important for the drug to be potent and long-lived. In an attempt to prevent
drug resistance while treating Mycobacterium tuberculosis, single-drug therapy aerosols
are not used (as reviewed by Sharma et al., 2001) and inhalable microparticles containing
multiple drugs in a dry powder are preferred (Sharma et al., 2001). In treating
Mycobacterium tuberculosis infection Isoniazid (H) and Rifampicin (R) are the two firstline anti-tuberculosis inhalant drugs of choice (Sharma et al., 2001). To test the potency
of H and R, mouse macrophages were exposed to equivalent amounts of H and R in a
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time spanning from 0 to 30 minutes. The macrophages were exposed to H and R
dissolved in culture medium and in microparticle form. Both H and R maintained higher
concentrations within the macrophages after 30 minutes in microparticle form as opposed
to the soluble form that presented a lower concentration within the macrophages (Fig. 51)
(Sharma et al., 2001).

FIG. 50 Both H and R maintain higher concentrations within alveolar macrophages in microparticle form.
Adapted from Sharma et al., 2001

In a three day study of mice infected with Mycobacterium tuberculosis, administration of
H and R aerosol resulted in the microparticles targeting alveolar macrophages of both the
Mycobacterium tuberculosis-infected mice and the uninfected control mice. Following
the administration of H and R, the macrophages of the mice were up to 50µm in diameter
and contained 10 or more particles. The alveolar macrophages also displayed no signs of
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intact mycobacteria, a finding that presents promise for the use of aerosols to treat
Mycobacterium tuberculosis infection (Fig. 52) (Sharma et al., 2007).

FIG. 51 Alveolar macrophages display no signs of intact mycobacteria following the administration H and
R aerosol. The arrow indicates electron-opaque debris. Adapted from Sharma et al., 2007

Effect of H and R on NO. Production
Intracellular RNIs are direct in their anti-mycobacterial function (Sharma et al.,
2007). An increase in NO. production indicates that alveolar macrophages have become
activated. Sharma et al. (2007) exposed uninfected alveolar macrophages and
Mycobacterium tuberculosis-infected alveolar macrophages to H and R drug containing
microparticles over a set period of 3, 9, and 24h. The results showed larger amounts of
NO. being produced 9h after infection with Mycobacterium tuberculosis when compared
to the untreated control. When equivalent amounts of H and R were used in solution, no
significant increases in NO. production were observed (Fig. 53) (Sharma et al., 2007).
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FIG. 52 H and R activate alveolar macrophages better in microparticle form than in solution at 3 (filled
bars), 9 (hatched bars) and 24 (white bars) h after treatment. ‘U+MP’ refers to uninfected cells treated with
microparticles, ‘Inf’ refers to cells receiving 25 moi of M. tuberculosis but no further treatment, ‘Inf+ D’
refers to infected cells exposed to drugs in solution and ‘Inf+ MP’ refers to infected cells treated with an
equivalent dose of microparticles.. Adapted from Sharma et al., 2007

These findings support the observation that inhaled microparticles have a greater effect
on alveolar macrophage activation than drugs in solution.
Effect H and R on Cytokine Production
To understand the effect that drug treatment has on Mycobacterium tuberculosis
infection, a three day experiment comparing TNF-α, IFN-γ, IL-10, and IL-12 cytokine
production by cells recovered from different mouse subjects was conducted. The results
showed an up-regulation of all four cytokines in untreated Mycobacterium tuberculosisinfected mice; however, there was no significant increase in IL-12 production. Oral drug
treatment with H and R down-regulated the production of all four cytokines while the
combination of oral and inhalant drug administration had no significant effect on any of
the cytokines. Inhalation drug treatment alone induced significant TNF-α production
and downregulated IFN-γ production (Fig. 54) (Sharma et al., 2007).

75

FIG. 53 Comparison of cytokine production by cells recovered from mice at 3 days postinfection.
Uninfected, untreated mice (XX); mice infected with M. tuberculosis H37Ra and left untreated (IX); or
infected and treated for 3 days with oral doses (IO), a combination of oral and inhalation dosing (IOI) or
inhalations alone (II). Adapted from Sharma et al., 2007

Of the four cytokines tested, TNF-α and IL-12 were the most significantly induced
following treatment with H and R microparticles (Fig. 55) (Sharma et al., 2007).

FIG. 54 TNF-α and IL-12 are induced the most following treatment with H and R microparticles. Neither
infection nor treatment (filled bars), infection alone (rising hatching), or infection with M. tuberculosis
followed by treatment with drugs in solution (cross-hatching), drug-containing microparticles (white bars)
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or blank, drug-free microparticles (falling hatching). Uninfected cells administered drug-containing
microparticles (vertical lines) served as an additional control. Adapted from Sharma et al., 2007

These findings continue to support the important roles that TNF-α and IL-12 have in
fighting Mycobacterium tuberculosis infection.
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DISCUSSION

Mycobacterium tuberculosis is a devastating disease that strategically evades
destruction by the host immune response. The innate and adaptive immune responses
triggered by this mycobacterium create a cascade of events that work to limit and contain
the growth of infection. The host defense mechanisms mounted against Mycobacterium
tuberculosis provides a glance into how the body naturally attempts to fight this disease
and are summarized in Table 4 and Figure 55.
Macrophage apoptosis is hypothesized to contribute to the host innate immune
response by containing and limiting the growth of tubercle bacilli. The study conducted
by Kelly et al. (2008) addressed the possibility of bystander apoptosis where uninfected
bystander cells undergo apoptosis as a way to prevent the dissemination of infection. It
was concluded that bystander apoptosis was not due to the release of soluble factors by
apoptotic Mycobacterium tuberculosis-infected macrophages but rather the result of cellcell contact between the infected apoptotic cells and the uninfected bystander cells. Cellcell contact between the infected and uninfected cells may have been required for
apoptosis to occur, but Kelly et al. (2008) failed to investigate the mechanism responsible
for the cell-cell contact-induced apoptosis of the uninfected bystander cells. It would
have benefited them to take the experiment a step further to investigate the reason for this
occurrence by considering the participation of gap junctions or the interaction of cell
surface molecules with one another. Because no further experimentation was conducted
to explain the mechanism behind the cell-cell contact-induced apoptosis, their findings
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have to be interpreted with great caution and perhaps a follow-up study designed to
address how cell-cell contact-induced apoptosis occurred should be conducted.
Nitric oxide (NO.) is one of the few bactericidal agents produced by infected
macrophages that is capable of killing Mycobacterium tuberculosis. Miller et al. (2004)
showed that iNOS is recruited to phagsomes not containing mycobacteria and Davis et al.
(2007) showed that iNOS is only recruited to phagosomes containing dead mycobacteria.
The combined findings from both experiments show that live mycobacteria have a way of
disrupting the recruitment of iNOS to infected phagosomes and it encourages the
progression of Mycobacterium tuberculosis infection. Further experimentation by Miller
et al. (2004) and Davis et al. (2007) showed that alterations or deletions in one or more of
the elements contributing to the action of the actin cytoskeleton can interfere with
microfilament motility and disrupt the recruitment of iNOS to phagosomes.
iNOS gene-disrupted mice (NOS2-/-) displayed a higher bacterial burden in their
lungs following Mycobacterium tuberculosis infection, however they were able to mount
an adaptive immune response comparable to that of wild-type mice (Beisiegel et al.,
2009). The fact that NOS2-/- mice had an infiltration of IFN-γ- and TNF-α-producing
CD4+ and CD8+ T cells similar to that of wild-type mice but still succumbed to infection
strongly supports the notion that NO. production is vital for fighting Mycobacterium
tuberculosis infection. The results from their experiment also suggest that
proinflammatory cytokines alone are not enough to fight Mycobacterium tuberculosis
infection in NOS2-/- mice.
The hypothesis that human alveolar macrophages are capable of producing NO. in
the event of Mycobacterium tuberculosis infection was confirmed in a studies by Rich et
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al. (1997) and Wang et al. (1998). Rich et al. (1997) showed that supernatant from
human Mycobacterium tuberculosis-infected alveolar macrophages contained NO. that
could be inhibited through the use of a iNOS inhibitor. Wang et al. (1998) conducted a
clinical study that fell in line with the results given by Rich et al. (1997). Wang et al.
(1998) showed that patients with active Mycobacterium tuberculosis infection had
significantly higher levels of NO. exhaled in their breath than healthy control subjects.
Further experimentation revealed that iNOS expression by the alveolar macrophages of
the tuberculosis patients was significantly higher than the control subjects and that the
increase in iNOS expression correlated with the level of exhaled NO.. The findings from
this clinical study have the potential to be used as a screening tool for people suspected of
harboring Mycobacterium tuberculosis infection. Since the level NO. exhaled in the
breath of the tuberculosis patients correlated with the amount of NO. being produced,
perhaps breathalyzer screenings could be used to determine the existence of a
mycobacterial infection and its seriousness.
TLR2 and TLR4 have displayed their importance in limiting and controlling the
advancement of Mycobacterium tuberculosis. In the absence of TLR2 and/or TLR4,
infection with Mycobacterium tuberculosis was shown to be fatal in mutant mice.
Following infection with Mycobacterium tuberculosis, TLR2- and TLR4-deficient mice
displayed bacterial burdens in their lungs that were significantly higher than the bacterial
burdens present in the wild-type control mice. The mice were ultimately shown to have
a large decrease in IL-12 production (Reiling et al., 2002) which is hypothesized to be
responsible for their increased susceptibility to infection with Mycobacterium
tuberculosis. This finding is of great importance because IL-12 is a proinflammatory
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cytokine produced upon TLR activation and in essence bridges the innate and adaptive
immune responses through CD4+ T cell recruitment and NK cell activation. Without
adequate IL-12 production, receiving aid from other innate immune components such as
γδ T cells or the proinflammatory cytokines IFN-γ and TNF-α is inhibited and results in
uncontrollable growth of tubercle bacilli.
γδ T cells contribute to the proinflammatory responses triggered upon infection
with Mycobacterium tuberculosis. In a study conducted by Li et al. (1998) patients with
active tuberculosis infection were shown to have a significantly reduced number of
Mycobacterium tuberculosis-reactive γδ T cells in their blood and bronchoalveolar lavage
(BAL) both before and after receiving drug chemotherapy. The decrease in the number
of Mycobacterium tuberculosis-reactive γδ T cells was attributed to the progression and
severity of infection in the patients. The problem with this conclusion is that the type of
drug treatment chosen to treat the Mycobacterium tuberculosis infection is one that is
non-specific and kills infected cells as well as healthy cells. Active disease patients and
patients with latent disease were administered chemotherapy for a time span of 2 to 16
months. At the 2 month mark only the active disease patients’ γδ T cell numbers were
counted. Beyond 2 months, both the active and latent disease patients’ γδ T cell numbers
were counted.

This presents a problem because the counting of the γδ T cells for the 2

patient groups was not consistent throughout the experiment. Since the γδ T cell numbers
of patients with latent Mycobacterium tuberculosis was not measured 2 months after drug
chemotherapy, how can it be concluded that they regained their γδ T cell numbers after
16 months of treatment? I understand that healthy individuals cannot be administered
chemotherapy treatments for experimental purposes; however, Li et al. (1998) concluded
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that the γδ T cell numbers of the active tuberculosis patients was significantly decreased
despite the experimental length. Without the use of a healthy control to undergo the same
treatment regimen to see exactly how their γδ T cell numbers are affected following drug
chemotherapy, how can it be concluded that the decrease seen in the γδ T cell numbers of
the tuberculosis patients is really as significant as the experiment claims? Perhaps to
address this question future studies should be performed using mice so that the extent of
the effect that drug chemotherapy places on γδ T cell numbers in healthy subjects, active,
and latent Mycobacterium tuberculosis-infected subjects can be observed.
Lockhart et al. (2006) conducted a study to show that γδ T cells and other nonCD4+ or CD8+ T cells are capable of producing IL-17 during Mycobacterium
tuberculosis infection. The findings from their study show that γδ T cells produce more
IL-17 than CD4+ T cells however, the way that they present their conclusion is
misleading. Purified cells from Mycobacterium tuberculosis-infected mice were
fractioned into three groups but the group referred to as the “CD4 pool” consisted of
more than CD4+ T cells. The “CD4 pool” also included CD8+ T cells and B cells. The
results from their experiment are misleading because if it is concluded that other nonCD4+ cells are capable of producing IL-17, then it only makes sense to have a group only
consisting of CD4+ cells to serve a control. It would have possibly been more accurate to
refer to the “CD4 pool” as the “adaptive immune cell pool” considering that all of the
cells in the group are involved in adaptive immunity.
Peng et al. (2008) showed that the percentage of IFN-γ-producing γδ T cells was
lower than the percentage of IL-17-producing γδ T cells in tuberculosis patients. It is
hypothesized that IFN-γ regulates the IL-17 response and that IL-17 can in return regulate
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the IFN-γ response. The results from their study suggest that the inability of tuberculosis
patients to produce enough IFN-γ to dampen IL-17-mediated inflammation during
Mycobacterium tuberculosis infection predisposes them to inappropriate tissue-damaging
responses. I on the other hand interpret their results a little differently. The way that I
interpret their findings is that if IL-17 is placing a damper on the IFN-γ responses, then
macrophage activation, CD8+ T cell recruitment, and most importantly NO. production
will be decreased. As I see it, this damper on IFN-γ production allows for the existence
Mycobacterium tuberculosis infection, with IL-17 aiding in its survival.
The development of more effective drugs and the search for better treatment
options for eradicating Mycobacterium tuberculosis remains ongoing. Despite the
development of different vaccine options, each one presents its own set of problems. For
instance, BCG is varies in its effectiveness, it has a waning efficacy, and is responsible
for false-positive TSTs. The CFP vaccine also has a waning efficacy and it needs to be
complexed with adjuvants. ESAT-6, like CFP, must be complexed with adjuvants. In
light of this, Sharma et al. (2001) showed that the drug form and the route of
administration can alter the effectiveness of the drug. In 2001, Sharma et al. proposed the
use of the inhalant drugs Isoniazid (H) and Rifampicin (R) to treat Mycobacterium
tuberculosis infection. Findings from their experiment showed that both H and R are
most effective in microparticle form as opposed to being dissolved in solution (Sharma et
al., 2001). Further studies in 2007 showed that the use of H and R in microparticle form
can promote macrophage activation and NO. production. In sync with the production of
NO. by activated macrophages, the proinflammatory cytokines IL-12 and TNF-α were
produced the most upon treatment with H and R (Sharma et al., 2007). As it currently
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stands, the use of inhalant microparticles is one of the most promising treatments in
trying to eliminate Mycobacterium tuberculosis infection.
TNF-α is a proinflammatory cytokine with a big responsibility in defending the
host against Mycobacterium tuberculosis. TNF-α is shown to play a key role in
granuloma formation and macrophage apoptosis. Mice that failed to produce adequate
amounts of TNF-α or had a disruption in the gene encoding for the 55kDa TNF receptor
(TNFRp55-/-) were unable to control infection and eventually died (Flynn et al., 1995).
More importantly, in humans, Saliu et al. (2006) showed that individuals undergoing
treatment with TNF-α blockers contract Mycobacterium tuberculosis infection at an
increased rate. The three popular commercial TNF-α inhibitor drugs are Humira,
Remicade, and Enbrel. Using these drugs, Saliu et al. (2006) showed that Humira and
Remicade act by inhibiting T cell activation and IFN-γ production whereas Enbrel does
not. The findings from their study is important because individuals being treated with
TNF-α inhibitor drugs for autoimmune diseases such as rheumatoid arthritis have a
higher risk of contracting Mycobacterium tuberculosis, specifically if they are using
Humira or Remicade. At the moment, Enbrel sounds the most promising in the event
that an individual with an autoimmune disease contracts Mycobacterium tuberculosis
infection because it still allows for the activation of T cells and the production of IFN-γ,
two elements absolutely necessary to successfully battle Mycobacterium tuberculosis
infection.
New strides are being made to advance the techniques used to study and develop a
cure for Mycobacterium tuberculosis. In recent years there has been more interest placed
into the role of vitamin D and its influence on Mycobacterium tuberculosis infection.
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African-Americans have an increased susceptibility to Mycobacterium tuberculosis
infection and usually have a more rapid and severe course of disease than CaucasianAmericans. Monocytes cultured in serum from African-Americans displayed vitamin D
levels that were significantly lower than the vitamin D levels from cultures containing
serum from Caucasian-Americans (Liu et al., 2006). This occurrence has been attributed
to the increased skin melanin content of African-Americans that causes decreased serum
levels of vitamin D (as reviewed by Liu et al., 2006).
Studies aimed at determining the role that vitamin D has in combating
Mycobacterium tuberculosis have displayed conflicting results. Whole blood analyses
from tuberculosis patients administered a single 2.5mg oral dose of vitamin D displayed
enhanced immunity (Martineau et al., 2007) and when vitamin D was added to
Mycobacterium tuberculosis-infected macrophages, the number of viable bacilli was
reduced (Liu et al., 2006). Both of these studies support the notion that vitamin D
promotes macrophage activation and helps to suppress the growth of Mycobacterium
tuberculosis. On the other hand, vitamin D has been shown to elicit a suppressive effect
on the production of T H 1 cytokines, specifically IFN-γ and TNF-α. Prahbu et al. (2009)
showed that vitamin D suppresses the production of both IFN-γ and TNF-α by CD4+ and
CD8+ T cells. Another experiment analyzing the effects of vitamin D on cytokine
production showed that tuberculosis patients had a significant decrease in the amount of
IFN-γ and IL-12 produced by their PBMCs (Vidyarani et al., 2007). These findings
however, suggest a role for vitamin D in reducing inflammation within the lungs of
Mycobacterium tuberculosis-infected individuals.
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The study of cholesterol is another avenue that is being explored to uncover its
influence on the incidence of Mycobacterium tuberculosis infection. Cholesterol is a
structural component of cellular membranes and it accumulates at the site of
mycobacterial uptake in macrophages (Pieters et al., 2002). Infected mouse macrophages
accumulated cholesterol at the site of bacterial entry while cholesterol of uninfected
macrophages remained distributed within the plasma membrane (Gatfield et al., 2000).
Mycobacteria bind to cholesterol with high affinity, so in an attempt to uncover the exact
role of cholesterol in the phagocytosis of tubercle bacilli, cholesterol was depleted from
the macrophages and the macrophages were observed for the uptake of the tubercle
bacilli. The results showed an 85% reduction in the phagocytosis of tubercle bacilli
(Gatfield et al., 2000). Gatfield et al. (2000) showed that the presence of cholesterol is
required for the phagocytosis of tubercle bacilli. With this information future studies
could focus on identifying the components of mycobacteria that bind to cholesterol. Such
findings could lead to strategies that interfere with cholesterol-mediated phagocytosis of
mycobacteria (Pieters et al., 2002). Gatfield et al. (2000) also showed that a depletion of
cholesterol on the cell surface of macrophages could decrease phagocytosis of tubercle
bacilli however; depleting cholesterol from the surface of macrophages may not serve as
the best method to prevent Mycobacterium tuberculosis infection given that cholesterol
has multiple roles in insuring the proper function of cells. In this case I think more
research is needed to determine whether the act of reducing or completely depleting
cholesterol from the surface of macrophages is more detrimental to the function of the
macrophages in the long run despite the initial benefit that it offers in helping to prevent
the uptake of tubercle bacilli.
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Regardless of the direction that future studies decide to take I think that future
animal studies should focus more on animals harboring latent Mycobacterium
tuberculosis infection. By focusing on animals with latent infection, it could possibly
lead to the design of new treatment options for humans harboring latent Mycobacterium
tuberculosis infection. Finding a new way to battle and creating a cure for latent
Mycobacterium tuberculosis infection will dramatically reduce the incidence of disease
within the human population. Animal models should also focus on animals that have
been previously vaccinated with the BCG vaccine. Focusing on these animals will allow
for the study and possible development of a way to prolong the effectiveness and
longevity of the BCG vaccine. The problem with current animal models is that most of
them look at immune reactions in short-term assays and these type of assays do not allow
time to access the vaccine’s longevity and the degree to which memory cells are or can be
formed. Lastly, because Mycobacterium tuberculosis affects the production of the
cytokines necessary for the successful containing and killing of infection, future drug
treatments should consider adding cytokines such as TNF-α, IFN-γ or IL-12 to vaccines
and aerosols as a means to help drive T cell recruitment and activation and NO.
production.
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Table 4 Summary of Observations
Summary of Observations
Mycobacterium tuberculosis
• Second leading cause of death among all infectious diseases worldwide
• Approximately 2 million people die each year from this disease
• One-third of the world’s population remains infected
Apoptosis
• Cell-cell contact between Mycobacterium tuberculosis-infected and uninfected
macrophages is required to induce bystander apoptosis
Inducible Nitric Oxide Synthase (iNOS)
• Mycobacteria-free phagosomes are capable of recruiting iNOS
•

Phagosomes containing heat-killed mycobacteria have no effect on iNOS recruitment
to phagosomes

•

iNOS recruitment is disrupted in phagosomes containing live mycobacteria

•

Alterations or deletions in one or more of the actin cytoskeleton elements can
interfere with actin microfilament motility, disrupting the recruitment of iNOS to
phagosomes
iNOS gene-disrupted mice (NOS2-/-) have a higher bacterial burden in their lungs
following Mycobacterium tuberculosis infection
NOS2-/- mice are capable of mounting an adaptive immune response comparable to
wild-type control mice upon challenge with Mycobacterium tuberculosis
Human Mycobacterium tuberculosis-infected alveolar macrophages are capable of
producing NO.
Patients with active Mycobacterium tuberculosis infection exhale significantly higher
levels of NO. than healthy control subjects
iNOS expression by alveolar macrophages of tuberculosis patients is significantly
higher than control subjects

•
•
•
•
•
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TLR2 and TLR4
• Neither TLR2/TLR4 is effective in providing a significant innate immune response
alone
•

Mice deficient in TLR2/TLR4 have a significantly higher bacterial burden than wildtype mice

γδ T cells
• Patients with active tuberculosis infection have a significantly reduced number of
Mycobacterium tuberculosis-reactive γδ T cells in their blood and BAL
•
•

γδ T cells produce IFN-γ in response to Mycobacterium tuberculosis only
γδ T cells are capable of producing more IFN-γ on a per cell basis than CD4+ T cells
in response to tubercle bacilli

•

γδ T cells proliferate faster in a high NK cell-percentage population than in a low NK
cell-percentage population

IL-17
• The percentage of IL-17-producing γδ T cells is significantly higher in tuberculosis
patients than in the healthy donors
•

γδ T cells and other non-CD4+ or CD8+ T cells are capable of producing IL-17 during
Mycobacterium tuberculosis infection

•

γδ T cells produce more IL-17 than CD4+ T cells

•

IFN-γ-deficient mice produced more IL-17 than wild-type mice

CD4+ and CD8+ T cells
• CD4+ T cells are two-fold more abundant than CD8+ T cells at sites of
Mycobacterium tuberculosis infection in both mice and humans
•

There is a significant reduction in the specific lysis mediated by cytotoxic CD8+ T
cells in the lungs of CD4-deficient mice

•

The cytotoxic activity of Mycobacterium tuberculosis-specific CD8+ T cells is
compromised in the absence of CD4+ T cells

•

In humans, CD4+ T cells are the primary source of IFN-γ but CD8+ T cells also
contribute to IFN-γ production
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BCG Vaccine
• Variable in its degree of protection against Mycobacterium tuberculosis infection
•

Efficacy wanes with time

•

Administration of the BCG vaccine during infancy is shown to be highly effective in
protecting against severe cases of tuberculosis

•

BCG vaccination of individuals after the first year of life results in persistent
tuberculin reactions

•

The United States and other industrialized countries with low incidences of
Mycobacterium tuberculosis infection have discontinued the use of the BCG vaccine

•

BCG vaccination affects tuberculin skin tests (TSTs)

Culture filtrate protein (CFP) vaccines
• Encourages competition for antigen presentation
•

Different culture conditions and the risk of the vaccine possessing both protective
and deleterious molecules makes it challenging to work with

•

Immunization with CFP antigens generate CD4+ T cells that secrete IFN-γ

•

Efficacy wanes with time

• CFP has to be delivered in adjuvant
Early Secretory Antigenic Target of 6kDa (ESAT-6)
• ESAT-6 enhances IFN-γ-induced accumulation of iNOS
•

ESAT-6 has to be complexed with multiple strong adjuvants to mount a sufficient
immune response
Inhalant drugs: Isoniazid (H) and Rifampicin (R)
• Microparticle form has a better effect on alveolar macrophage activation
•

TNF-α and IL-12 are the most significantly induced cytokines following treatment
with H and R microparticles
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Important proinflammatory cytokines
IL-12
• Humans and mice with mutations in either the IL-12p40 gene or IL-12R gene show a
reduction in IFN-γ production
•

IL-12 links innate and adaptive immunity

IFN-γ
• Humans and mice with mutations in either the IFN-γ gene or IFN-γR gene are highly
susceptible to mycobacterial infections
•

NO. production is significantly increased in Mycobacterium tuberculosis-infected
PBMCs stimulated with IFN-γ

TNF-α
• Neutralization of TNF-α impairs the ability of the mice to control Mycobacterium
tuberculosis infection
•

Mice with a disruption in the gene encoding for the 55kDa TNF receptor

(TNFRp55-/-) are unable to control Mycobacterium tuberculosis infection
TNF-α increases Mycobacterium tuberculosis-induced NO. production by alveolar macrophages

•

The presence of sTNFR decreases TNF-α-induced apoptosis

•

Individuals treated with TNF-α blockers contract Mycobacterium tuberculosis
infection at an increased rate

•

Humira and Remicade inhibited T cell activation and IFN-γ production whereas
Enbrel does not
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FIG.55 Summary of Host Pro-Inflammatory Defense Mechanisms
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